Pharmaceutical composition containing allopregnanolone, ganaxolone or zulanolone and use thereof

By using the combination of large particles and small particles in the pharmaceutical composition, the rapid achievement of benzanolone and ganesolone and the long-term maintenance of high plasma concentrations is achieved, and the low bioavailability and effect in the prior art are solved. The problem of poor durability simplifies the application process.

CN113939299BActive Publication Date: 2024-12-06BRII BIOSCIENCES LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080042380.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-05-01
Filing Date
2020-05-08
Publication Date
2024-12-06
Estimated Expiration
2040-05-08

AI Technical Summary

Technical Problem

The existing intravenous injection products of pegrinolone and ganaxolone are in the treatment of postpartum depression and childhood epilepsy, and there are problems such as low bioavailability, poor durability and inconvenient administration. A novel preparation is needed to improve the biologics. Utilization and durability of action and simplify the application process.

Method used

A pharmaceutical composition containing a positive regulator of γ-aminobutyric acid type A receptor was developed, and the particle size distribution of the drug was adjusted by intramuscular or subcutaneous injection, using the combination of large particles and small particles to achieve rapid achievement. Maximum plasma concentration and maintain high concentration for a long time.

Benefits of technology

Maximum plasma concentrations were achieved within 30 minutes to 6 hours and maintained plasma concentrations greater than 5% in subjects for at least 5 days, improving the bioavailability of the drug and durability of the effect and simplifying the administration process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113939299B_ABST
    Figure CN113939299B_ABST
Patent Text Reader

Abstract

The present disclosure relates to a pharmaceutical composition comprising a pharmaceutically effective amount of a neuroactive steroid, wherein the steroid is a gamma-aminobutyric acid type A (GABA A ) receptor positive regulator. Also disclosed are a method for treating a disease using the pharmaceutical composition and a method for producing the pharmaceutical composition.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-references

[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 846,576, filed May 10, 2019, and U.S. Provisional Application No. 63 / 018,815, filed May 1, 2020, each of which is incorporated herein by reference in its entirety. Technical Field

[0003] The present disclosure relates to a pharmaceutical composition comprising brexanolone, ganaxolone, zuranolone (SAGE-217), or a combination thereof, for use in treating diseases such as depression associated with epilepsy and other central nervous system disorders. Background Art

[0004] Many endogenous and synthetic compounds, such as neuroactive steroids and derivatives, can affect central nervous system (CNS) function through a variety of mechanisms, including but not limited to GABA, which is associated with many CNS disorders. A (gamma-aminobutyric acid type A) receptors. Allopregnanolone is one of these neuroactive steroids that has a short terminal half-life and poor oral bioavailability and has limited clinical use as an oral or parenteral therapy. Allopregnanolone is a synthetic compound that is chemically identical to endogenous sex pregnenolone. Ganaxolone, another such neuroactive steroid and a synthetic pregnane steroid, has a relatively long half-life, is present in human plasma for approximately 20 hours after oral administration, and has a maximum concentration (T max ) is smaller (U.S. Patent Application Publication No. 20160228454). Ganaxolone and allopregnanolone can both regulate GABA A Receptor activity (PCT Patent Publication Nos. WO2017156103A1, WO2016127170A1, U.S. Patent Nos. 9,029,355, 9,452,176, 10,172,870).

[0005] Recently, allopregnanolone intravenous products (allopregnanolone IV, ZULRESSO TM, developed and marketed under the trademark of Sage Therapeutics, Cambridge, MA, USA) was approved by the US Food and Drug Administration (FDA, March 2019) for the treatment of postpartum depression (PPD), a serious and potentially life-threatening condition for which drug therapy is not currently clearly indicated. However, ZULRESSO TM It is conveniently used and administered to patients by continuous intravenous (IV) infusion, which lasts for a total of about 60 hours (2.5 days).

[0006] Recently, ganaxolone has been successfully tested in clinical trials for the treatment of severe postpartum depression (PPD) and childhood epilepsy (Marinus Pharmaceuticals). Both intravenous and oral formulations of ganaxolone have been developed and tested (U.S. Patent Publication No. 20160228454A1; Clinical Trial ID: NCT03228394, MAGNOLIA trial; Ligsay et al., Journal of Neurodevelopmental Disorders, 9:26, 2017; Rasmusson et al., Psychopharmacology, 234:2245-2257, 2017, DOI 10.1007 / s00213-017-4649-y). However, the effects of these formulations still need to be optimized.

[0007] Therefore, there is a need for new and improved formulations with enhanced bioavailability, prolonged action, and / or rapid and convenient delivery. Summary of the invention

[0008] In one aspect, disclosed herein is a pharmaceutical composition comprising a pharmaceutically effective amount of a neuroactive steroid, wherein the neuroactive steroid is gamma-aminobutyric acid type A (GABA A ) receptor positive modulator; and wherein after a single dose of the pharmaceutical composition is administered by intramuscular or subcutaneous injection, the plasma concentration of the neuroactive steroid reaches a maximum plasma concentration (C max ) and remain greater than the C max Plasma concentrations of about 5% of the drug persist for at least about 5 days.

[0009] Also disclosed is a pharmaceutical composition comprising particles comprising at least one neuroactive steroid and one or more pharmaceutically acceptable excipients, wherein the neuroactive steroid is gamma-aminobutyric acid type A (GABA A) receptor positive modulator; wherein the particles comprise large particles having a particle size in the range of about 1.5 μm to about 15 μm and small particles having a particle size in the range of about 0.2 μm to about 1.5 μm; and wherein about 0.01% to about 50% of the particles are small particles and about 50% to 99.99% of the particles are large particles, the percentages being based on the total weight of the particles. The neuroactive steroid may be GABA A A positive modulator of a receptor and may include tetrahydrodeoxycorticosterone (THDOC), androstane, androstane 3α-androstanediol, cholestane cholesterol, pregnane, pregnenolone (eltanolone), allopregnanolone, allopregnanolone, ganaxolone, zuranolone (SAGE-217), or a combination thereof.

[0010] In another aspect, disclosed herein is a method for producing a pharmaceutical composition comprising particles, the method comprising: a) producing a particle mixture comprising: a neuroactive steroid selected from allopregnanolone, ganaxolone, zulanolone (SAGE-217), or a combination thereof, and one or more pharmaceutically acceptable excipients; b) milling a first portion of the particle mixture to produce a large particle mixture, wherein at least 50% of the large particle mixture is large particles having a particle size in the range of about 1.5 μm to about 15 μm, the percentage being based on the total weight of the particle mixture; and c) producing a pharmaceutical composition comprising the particles, the particles comprising about 50% to 99.99% large particles, the percentage being based on the total weight of the particles.

[0011] In another aspect, disclosed herein is a method for treating a disease in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition disclosed herein or a pharmaceutical composition produced by a method disclosed herein. The pharmaceutical composition can be administered to the subject by intramuscular (IM) injection, subcutaneous (SC) injection, intravenous (IV) injection, or a combination thereof.

[0012] Also disclosed is a method of treating a disease in a subject in need thereof, the method comprising: administering to the subject a pharmaceutical composition comprising a pharmaceutically effective amount of a neuroactive steroid in a single dose in the range of 0.5 to 10 mg per kilogram of the subject's body weight by intramuscular or subcutaneous injection, wherein the neuroactive steroid is gamma-aminobutyric acid type A (GABA A ) receptor positive modulator; and wherein after administering the pharmaceutical composition to the subject by intramuscular or subcutaneous injection, the plasma concentration of the neuroactive steroid reaches a maximum plasma concentration (C max ) and remain greater than C in the subject max Plasma concentrations of about 5% of the drug persist for at least about 5 days.

[0013] Incorporated by Reference

[0014] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1A-Figure 1D . Schematic representation of exemplary particle size distributions. Figure 1A : The pharmaceutical composition comprises a very small amount of small particles, such as less than 1%, and mainly comprises large particles. Figure 1B : The pharmaceutical composition comprises some small particles and mainly comprises large particles. Figure 1C : The pharmaceutical composition comprises increasing amounts of small particles and large particles. Figure 1D : The pharmaceutical composition contains similar amounts of small and large particles. D50 = Mass Median Diameter (MMD) where 50% of the particles are smaller than a given diameter and 50% of the particles are larger than a given diameter. Mean Large = Average particle size of large particles. Mean Small = Average particle size of small particles.

[0016] Figure 2A-2E Examples of pharmaceutical compositions comprising allopregnanolone. Figure 2A : Allopregnanolone structure. Figure 2B : Smaller pregnanolone particle size distribution. Figure 2C : Larger particle size distribution of pregnanolone. Figure 2D-Figure 2E : Pharmacokinetics (PK) of rat plasma allopregnanolone concentrations in rats showing changes over time after administration. Legend: open diamonds, small particle allopregnanolone suspension, 25 mg / kg; open squares, large particle allopregnanolone suspension, 25 mg / kg; closed squares, IV solution (comparator) 1 mg / kg; and closed triangles, IM solution (comparator) 12.5 mg / kg.

[0017] Figure 3A-3E Examples of pharmaceutical compositions comprising ganaxolone. Figure 3A : Ganaxolone structure. Figure 3B : Distribution of 4.1 μm ganaxolone particles. Figure 3C : Distribution of 3.6 μm ganaxolone particles. Figure 3D-Figure 3E : Pharmacokinetics (PK) in rats showing rat plasma concentrations over time after administration. Legend: open diamonds, ganaxolone suspension with 1 μm particles, 25 mg / kg; open squares, ganaxolone suspension with 4 μm particles, 25 mg / kg; closed squares, IV solution (comparator); and closed diamonds, IM solution (comparator).

[0018] Figure 4 Summary of the crystal screening results under three conditions: 1) temperature cycle aging of the allopregnanolone slurry between 40°C and 5°C for two days (TC) (n=48); 2) heating the slurry to 40°C followed by hot filtration and subsequent storage of the allopregnanolone solution at 4°C for up to two days (RC) (n=48); 3) evaporation of the allopregnanolone solution under ambient conditions for up to 7 days (EV) (n=48).

[0019] Figure 5 Overlay of the PXRD pattern of Form A from allopregnanolone input with a representative Form A pattern from the screen. DETAILED DESCRIPTION

[0020] Those of ordinary skill in the art will more easily understand the features and advantages of the disclosed compositions and methods after reading the following detailed description. It should be understood that, for clarity, in the context of a separate embodiment, some features of the disclosed compositions and methods described above and below may also be provided in a single embodiment in combination. On the contrary, for simplicity, the various features of the disclosed compositions and methods described in the context of a single embodiment may also be provided separately or in any sub-combination. In addition, unless the context clearly states otherwise, a singular reference may also include a plural number (e.g., "one / kind" may refer to one / kind or one / kind or multiple / kinds).

[0021] Unless otherwise expressly indicated, the use of numerical values ​​specified in various ranges in this application is stated as approximate values, such as the minimum and maximum values ​​within the stated ranges are generally followed by the word "about". In this way, slight variations above or below the stated ranges can be used to achieve substantially the same results as the values ​​within the stated ranges. In addition, the disclosure of these ranges is intended as a continuous range including every value between the minimum and maximum values.

[0022] As used herein, the term "about" and its grammatical equivalents associated with a reference numerical value and its grammatical equivalents can include a series of values ​​of plus or minus 10% of the value, such as a series of values ​​of plus or minus 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1%. For example, the amount "about" 10 includes an amount of 9 to 11.

[0023] As used herein, the terms "γ-aminobutyric acid type A receptor", "γ-aminobutyric acid type A receptor", "γ-aminobutyric acid A receptor", "GABA A receptors", "GABA A Rs", "GABA A R" or its grammatical variations refers to gamma-aminobutyric acid type A receptor (GABA ARs), which are a type of receptor that responds to the neurotransmitter gamma-aminobutyric acid (GABA). GABA is the main inhibitory neurotransmitter in the cerebral cortex and is essential for maintaining an inhibitory state that counteracts neuronal excitation. GABA A Dysregulation of receptors or an imbalance between GABA and neuronal excitation can lead to epileptic seizures and other central nervous system disorders. Many natural and synthetic neuroactive steroids can interact with GABA A Rs bind and regulate its activity.

[0024] The term "neuroactive steroid" or "neuroactive steroids" or grammatical variations thereof refers to one or more steroids that have an effect on neurotransmission, particularly on GABA. A Neurosteroids that exert inhibitory effects on receptors. Examples of neurosteroids may include, but are not limited to, tetrahydrodeoxycorticosterone (THDOC), androstane, androstane 3α-androstanediol, cholestane cholesterol, pregnane, pregnenolone (ethanolone), allopregnanolone, allopregnanolone, ganaxolone, and zuranosolone (SAGE-217).

[0025] The term "particle" or grammatical variations thereof may refer to the particles disclosed herein, and in examples may also refer to stabilized particles that are stable under physiological conditions and do not change their physical or chemical form for a longer period of time, such as for a period of time in the following range: 0.1 to 20 hours, 1 to 50 hours, 2 to 75 hours, 5 to 100 hours, 1 to 5 days, 2 to 7 days, 3 to 10 days, 4 to 20 days or longer.

[0026] The terms D10, D50, and D90 are often used to represent the midpoint and particle size range of a given sample. The term "D10" means that 10% of the particles are below and 90% of the particles are above a defined measure, such as a particle diameter. The term "D50" refers to the mass median diameter (MMD), where 50% of the particles are below and 50% of the particles are above a defined measure, such as a particle diameter. The term "D90" means that 90% of the particles are below and 10% of the particles are above a defined measure, such as a particle diameter. In an example, D50 = 1.5 μm means that 50% of the particles are less than 1.5 μm and 50% of the particles are greater than 1.5 μm. In other examples, D90 = 4.0 μm means that 90% of the particles are less than 4.0 μm in diameter and 10% of the particles are greater than 4.0 μm in diameter. The percentages may be based on the total volume of the particles measured, the total weight of the particles, the total number of particles, or the total area of ​​the particles. In an example, by using about 1×10 6The particle size is measured by performing light scattering on the particles measured. The measured data of D50=0.9 μm means that about 50% of the measured particles are less than 0.9 μm and 50% are greater than 0.9 μm, and the percentage is based on the total number of particles measured. In other examples, the particle size is measured using microscopy and imaging techniques or optical particle measurement, in which particles in a specific range are measured. In this regard, the percentage can be the total number of particles measured or a given area measured.

[0027] The term "particle size" refers to the crystallite size of the major particle size or the smallest particle size. When particles of the major size are aggregated together, the aggregates may have an aggregate particle size that is generally a multiple of the major particle size. Particle size as used herein refers to the largest dimension of the major particle, such as the diameter of a spherical particle, the maximum length of a rod-shaped or rod-shaped particle, or the largest dimension measured in an irregularly shaped particle.

[0028] The term "average particle size" refers to the average of the particle sizes of measured or selected particles.

[0029] The term "C max ,” “Cmax” or “maximum plasma concentration” refers to the highest (or peak) plasma concentration that a drug reaches in a particular compartment or site of the body after the drug has been administered and before a second dose is administered.

[0030] Pharmaceutical composition

[0031] The disclosed pharmaceutical composition may comprise a pharmaceutically effective amount of a neuroactive steroid, wherein the neuroactive steroid is a gamma-aminobutyric acid type A (GABA A ) receptor positive modulator; and wherein after intramuscular or subcutaneous injection of a single dose of the pharmaceutical composition, the neuroactive steroid reaches a maximum plasma concentration (C max ) and remain greater than C max A plasma concentration of about 5% of the drug persists for at least about 1 day.

[0032] The pharmaceutical composition may include a pharmaceutically effective amount of a neuroactive steroid, wherein the amount of the neuroactive steroid that can be combined with a carrier material to produce a single dosage form can vary depending on the subject to be treated and the specific mode of administration, and can generally be an amount of the pharmaceutical composition that produces a therapeutic effect. Generally speaking, the amount of the neuroactive steroid can range from about 0.01% to about 99% (w / w) of the composition, for example, about 0.1%-1%, about 0.1%-5%, about 0.1-10%, about 0.1%-20%, about 0.5%-1%, about 0.5%-5%, about 0.5%-10%, about 0.5%-20%, about 1%-5%, about 1%-10%, about 1%-20%, about 5 ...10%, about 1%-20 About 5%-20%, about 10%-20%, about 10%-30%, about 20%-30%, about 20%-40%, about 30%-40%, about 30%-50%, about 40%-50%, about 40%-60%, about 50%-60%, about 50%-70%, about 60%-70%, about 60%-80%, about 70%-80%, about 70%-90%, about 80%-90%, about 80%-95%, or 95%-99%. Preferably, the amount of neuroactive steroid can be about 0.1% to about 70% of the pharmaceutical composition, and most preferably about 1% to about 30%.

[0033] The pharmaceutical composition may comprise a pharmaceutically effective amount of a neuroactive steroid, wherein the neuroactive steroid is a gamma-aminobutyric acid type A (GABA A ) receptor positive modulator; wherein after a single dose of the pharmaceutical composition is administered to a subject by intravenous (IV) injection, intramuscular (IM) injection, subcutaneous (SC) injection, or a combination thereof, the neuroactive steroid reaches a maximum plasma concentration (C max ) and remain greater than C in the subjects max The maximum plasma concentration (C max ).

[0034] In some cases, Cmax can be reached in about 10 minutes to about 360 minutes. In some cases, Cmax can be reached in about 10 minutes to about 20 minutes, about 10 minutes to about 30 minutes, about 10 minutes to about 40 minutes, about 10 minutes to about 50 minutes, about 10 minutes to about 60 minutes, about 10 minutes to about 120 minutes, about 10 minutes to about 180 minutes, about 10 minutes to about 240 minutes, about 10 minutes to about 300 minutes, about 10 minutes to about 360 minutes, about 20 minutes to about 30 minutes, about 20 minutes to about 40 minutes, about 20 minutes to about 50 minutes, about 20 minutes to about 60 minutes. , about 20 minutes to about 120 minutes, about 20 minutes to about 180 minutes, about 20 minutes to about 240 minutes, about 20 minutes to about 300 minutes, about 20 minutes to about 360 minutes, about 30 minutes to about 40 minutes, about 30 minutes to about 50 minutes, about 30 minutes to about 60 minutes, about 30 minutes to about 120 minutes, about 30 minutes to about 180 minutes, about 30 minutes to about 240 minutes, about 30 minutes to about 300 minutes, about 30 minutes to about 360 minutes, about 40 minutes to about 50 minutes, about 40 minutes to about 40 minutes minutes to about 60 minutes, about 40 minutes to about 120 minutes, about 40 minutes to about 180 minutes, about 40 minutes to about 240 minutes, about 40 minutes to about 300 minutes, about 40 minutes to about 360 minutes, about 50 minutes to about 60 minutes, about 50 minutes to about 120 minutes, about 50 minutes to about 180 minutes, about 50 minutes to about 240 minutes, about 50 minutes to about 300 minutes, about 50 minutes to about 360 minutes, about 50 minutes to about 120 minutes, about 60 minutes to about 180 minutes, about 50 minutes to about 240 minutes, about 50 minutes to about 300 minutes, about 50 minutes to about 360 minutes, In some cases, Cmax may be reached within about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 120 minutes, about 180 minutes, about 120 minutes to about 240 minutes, about 120 minutes to about 300 minutes, about 120 minutes to about 360 minutes, about 180 minutes to about 240 minutes, about 180 minutes to about 300 minutes, about 180 minutes to about 360 minutes, about 240 minutes to about 300 minutes, about 240 minutes to about 360 minutes, or about 300 minutes to about 360 minutes. In some cases, Cmax may be reached within about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 120 minutes, about 180 minutes, about 240 minutes, about 300 minutes, or about 360 minutes.

[0035] In some cases, the neuroactive steroid can maintain a plasma concentration in a subject at a level greater than about 5% of Cmax for about 1 day to about 100 days. In some cases, the neuroactive steroid can maintain a plasma concentration in a subject at a level greater than about 5% of Cmax for at least about 1 day. In some cases, the neuroactive steroid can maintain a plasma concentration in a subject at a level greater than about 5% of Cmax for up to about 100 days. In some cases, the neuroactive steroid may maintain a plasma concentration in a subject at a level greater than about 5% of Cmax for about 1 day to about 5 days, about 1 day to about 10 days, about 1 day to about 20 days, about 1 day to about 30 days, about 1 day to about 50 days, about 1 day to about 100 days, about 5 days to about 10 days, about 5 days to about 20 days, about 5 days to about 30 days, about 5 days to about 50 days, about 5 days to about 100 days, about 10 days to about 20 days, about 10 days to about 30 days, about 10 days to about 50 days, about 10 days to about 100 days, about 20 days to about 30 days, about 20 days to about 50 days, about 20 days to about 100 days, about 30 days to about 50 days, about 30 days to about 100 days, or about 50 days to about 100 days. In some cases, the neuroactive steroid can maintain a plasma concentration in a subject at a level greater than about 5% of Cmax for about 1 day, about 5 days, about 10 days, about 20 days, about 30 days, about 50 days, or about 100 days.

[0036] In some cases, a single dose of the disclosed drug combination can be about 0.5 mg to about 50 mg per kilogram (kg) of body weight. In some cases, a single dose can be at least about 0.5 mg per kilogram of body weight. In some cases, a single dose can be up to about 50 mg per kilogram of body weight. In some cases, a single dose can be about 0.5 mg to about 2 mg per kilogram of body weight, about 0.5 mg to about 4 mg per kilogram of body weight, about 0.5 mg to about 6 mg per kilogram of body weight, about 0.5 mg to about 8 mg per kilogram of body weight, about 0.5 mg to about 10 mg per kilogram of body weight, about 0.5 mg to about 20 mg per kilogram of body weight, about 0.5 mg to about 50 mg per kilogram of body weight, about 2 mg to about 4 mg per kilogram of body weight, about 2 mg to about 6 mg per kilogram of body weight, about 2 mg to about 8 mg per kilogram of body weight, about 2 mg to about 10 mg per kilogram of body weight, about 2 mg to about 20 mg per kilogram of body weight, about 2 mg to about 50 mg per kilogram of body weight, about The present invention relates to an agent that is preferably used in an oral dosage form. The agent that is used in an oral dosage form is preferably a pharmaceutical composition comprising: a pharmaceutical composition having an oral dosage form, a pharmaceutical composition having an oral dosage form, a pharmaceutical composition having an oral dosage form, a pharmaceutical composition having an oral dosage form, a pharmaceutical composition having an oral dosage form, a pharmaceutical composition having an oral dosage form, a pharmaceutical composition having an oral dosage form, a pharmaceutical composition having an oral dosage form, a pharmaceutical composition having an oral dosage form, a pharmaceutical composition having an oral dosage form, a pharmaceutical composition having an oral dosage form, a pharmaceutical composition having an oral dosage form, a pharmaceutical composition having an oral dosage form, a pharmaceutical composition having an oral dosage form, a pharmaceutical composition having an oral dosage form, a pharmaceutical composition having an oral dosage form, a pharmaceutical composition having an oral dosage form, a pharmaceutical composition having an oral dosage form, a pharmaceutical composition having an oral dosage form, a pharmaceutical composition having an oral dosage form, In some cases, a single dose can be about 0.5 mg per kg body weight, about 2 mg per kg body weight, about 4 mg per kg body weight, about 6 mg per kg body weight, about 8 mg per kg body weight, about 10 mg per kg body weight, about 20 mg per kg body weight, or about 50 mg per kg body weight. In a specific example, a single dose can be about 3.5 mg to 5 mg per kg body weight. Body weight refers to the body weight of a subject such as a human patient or an animal subject.

[0037] In some cases, a unit dose of a disclosed pharmaceutical composition can be about 50 mg to about 800 mg. In some cases, a single unit dose can be at least about 50 mg. In some cases, a single unit dose can be up to about 800 mg. In some cases, a single unit dose can be from about 50 mg to about 100 mg, about 50 mg to about 200 mg, about 50 mg to about 300 mg, about 50 mg to about 400 mg, about 50 mg to about 600 mg, about 50 mg to about 800 mg, about 100 mg to about 200 mg, about 100 mg to about 300 mg, about 100 mg to about 400 mg, about 100 mg to about 600 mg, about 100 mg to about 800 mg, about 200 mg to about 300 mg, about 200 mg to about 400 mg, about 200 mg to about 600 mg, about 200 mg to about 800 mg, about 300 mg to about 400 mg, about 300 mg to about 600 mg, about 300 mg to about 800 mg, about 400 mg to about 600 mg, about 400 mg to about 800 mg, or about 600 mg to about 800 mg. In some cases, a single unit dose can be about 50 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 600 mg or about 800 mg. Unit dose is a packaged form of a pharmaceutical composition that can be administered to a subject in a single dose. For example, a 300 mg unit dose of pharmaceutical composition can be packaged in a specific volume, such as one milliliter of volume, which is an injectable form that can be injected into a subject in a single injection form. In other examples, a 300 mg pharmaceutical composition can be packaged in a specific number of tablets, such as a tablet, which can be administered to a subject in an oral dose. In other examples, a 300 mg unit dose of pharmaceutical composition can be packaged in a specific volume, such as 0.5 milliliter of volume, which is an injectable form that can be injected into a subject in a single subcutaneous injection form.

[0038] In some cases, a single dose of a disclosed pharmaceutical composition can be about 50 mg to about 800 mg. In some cases, a single dose can be at least about 50 mg. In some cases, a single dose can be up to about 800 mg. In some cases, a single dose can be about 50 mg to about 100 mg, about 50 mg to about 200 mg, about 50 mg to about 300 mg, about 50 mg to about 400 mg, about 50 mg to about 600 mg, about 50 mg to about 800 mg, about 100 mg to about 200 mg, about 100 mg to about 300 mg, about 100 mg to about 400 mg, about 100 mg to about 600 mg, about 100 mg to about 800 mg, about 200 mg to about 300 mg, about 200 mg to about 400 mg, about 200 mg to about 600 mg, about 200 mg to about 800 mg, about 300 mg to about 400 mg, about 300 mg to about 600 mg, about 300 mg to about 800 mg, about 400 mg to about 600 mg, about 400 mg to about 800 mg, or about 600 mg to about 800 mg. In some cases, a single dose may be about 50 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 600 mg, or about 800 mg.

[0039] When the unit dose is used to administer the pharmaceutical composition to the subject based on the subject's weight, the single dose can be adjusted. In one example, the unit dose of 300 mg in 1 mL of injectable solution is intended to be injected as a single dose to a subject whose body weight is within the range of 60 kg to 70 kg. For a subject with a body weight lower than 60 kg, the dose adjusted can be injected into the subject at one time, such as a 300 mg unit dose of 0.5 mL. For a subject with a body weight higher than 70 kg, the dose adjusted can be injected into the subject at one time, such as a 300 mg unit dose of 1.5 mL. As disclosed herein, a single dose can be adjusted to have a pharmaceutical composition with a desired number of milligrams per kilogram (kg) of body weight.

[0040] A single dose of the disclosed pharmaceutical composition may be in the range of about 0.5 to 50 mg per kilogram (kg) of body weight and / or may be produced by combining one or more unit doses or portions thereof, wherein each of the unit doses may be in the range of 50 mg to 800 mg per unit dose. The ranges of single doses, unit doses, or combinations thereof disclosed above and below are suitable and are incorporated as examples.

[0041] In some cases, the disclosed pharmaceutical compositions can have a neuroactive steroid concentration of about 5 mg / mL to about 800 mg / mL. In some cases, the neuroactive steroid concentration can be at least about 5 mg / mL. In some cases, the neuroactive steroid concentration can be up to about 800 mg / mL. In some cases, the neuroactive steroid concentration can be about 5 mg / mL to about 10 mg / mL, about 5 mg / mL to about 50 mg / mL, about 5 mg / mL to about 100 mg / mL, about 5 mg / mL to about 200 mg / mL, about 5 mg / mL to about 400 mg / mL, about 5 mg / mL to about 800 mg / mL, about 10 mg / mL to about 50 mg / mL, about 10 mg / mL to about 100 mg / mL, about 10 mg / mL to about 200 mg / mL, about 10 mg / mL to about 400 mg / mL, about 10 mg / mL to about 500 mg / mL. In some cases, the neuroactive steroid concentration can be about 5 mg / mL, about 10 mg / mL, about 50 mg / mL, about 100 mg / mL, about 200 mg / mL, about 400 mg / mL, about 800 mg / mL, about 100 mg / mL to about 200 mg / mL, about 100 mg / mL to about 400 mg / mL, about 100 mg / mL to about 800 mg / mL, about 200 mg / mL to about 400 mg / mL, about 200 mg / mL to about 800 mg / mL, or about 400 mg / mL to about 800 mg / mL. In some cases, the neuroactive steroid concentration can be about 5 mg / mL, about 10 mg / mL, about 50 mg / mL, about 100 mg / mL, about 200 mg / mL, about 400 mg / mL, or about 800 mg / mL.

[0042] In some cases, neuroactive steroids can remain above C max The neuroactive steroid may maintain a plasma concentration of about 10%, 15%, 20%, 25% or 30% of the plasma concentration for at least about 10, 20, 30, 40, 50 or 60 days. In one example, the neuroactive steroid may maintain a plasma concentration of greater than about 10% C max The plasma concentration is maintained for at least about 10 days, and in another embodiment, 15% C max for at least about 10 days, in yet another example maintaining 20% ​​C max for at least about 10 days, in yet another example maintaining 25% C max for at least about 10 days, in yet another example, at 35% C. max for at least about 10 days, in another example maintaining 10% C max For at least about 20 days, in another example, 15% C max for at least about 20 days, in yet another example maintaining 25% C maxfor at least about 20 days, in yet another example maintaining 35% C max for at least about 20 days, in another example maintaining 10% C max For at least about 30 days, in another example, 15% C max for at least about 30 days, in yet another example maintaining 25% C max for at least about 30 days, and in yet another example, at 35% C. max For at least about 30 days, in another example, 10% C max For at least about 40 days, in another example, 15% C max for at least about 40 days, and in yet another example, at 25% C. max for at least about 40 days, and in yet another example, at 35% C. max for at least about 40 days, in another example maintaining 10% C max For at least about 50 days, in another example, 15% C max for at least about 50 days, and in yet another example, at 25% C. max for at least about 50 days, and in yet another example, at 35% C. max For at least about 50 days, in another example, 10% C max For at least about 60 days, in another example, 15% C max for at least about 60 days, and in yet another example, at 25% C. max for at least about 60 days, and in yet another example, at 35% C. max for at least about 60 days, in another example maintaining 10% C max For at least about 60 days or more, in another example, 15% C max for at least about 60 days or more, in yet another example maintaining 25% C max for at least about 60 days or more, or in yet another example, at 35% C. max Continue for at least about 60 days or more. In a particular example, the neuroactive steroid can remain greater than C max Plasma concentrations of about 15% of the dose persist for at least about 30 days.

[0043] In some cases, C max Can be about 1 ng / mL to about 100 ng / mL. In some cases, C max Can be at least about 1 ng / mL. In some cases, C max Can be up to about 100 ng / mL. In some cases, C maxThe amount of the present invention may be from about 1 ng / mL to about 10 ng / mL, from about 1 ng / mL to about 20 ng / mL, from about 1 ng / mL to about 40 ng / mL, from about 1 ng / mL to about 60 ng / mL, from about 1 ng / mL to about 80 ng / mL, from about 1 ng / mL to about 100 ng / mL, from about 10 ng / mL to about 20 ng / mL, from about 10 ng / mL to about 40 ng / mL, from about 10 ng / mL to about 60 ng / mL, from about 10 ng / mL to about 80 ng / mL, from about 10 ng / mL to about 100 ng / mL, In some cases, C max Can be about 1 ng / mL, about 10 ng / mL, about 20 ng / mL, about 40 ng / mL, about 60 ng / mL, about 80 ng / mL or about 100 ng / mL. In a specific example, C max It is in the range of 20 to 90 ng / mL.

[0044] In some cases, a single dose may be in the range of 3 to about 5 mg per kg of body weight, and / or the neuroactive steroid may maintain a plasma concentration of greater than about 10 ng / mL for at least about 5 days. In a particular example, the neuroactive steroid may maintain a plasma concentration of greater than 10, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100 ng / mL for at least about 10, 20, 30, 40, 50 or 60 days. In some cases, the neuroactive steroid can maintain a plasma concentration of greater than 10 ng / mL in one example for at least about 10 days, greater than 20 ng / mL in another example for at least about 10 days, greater than 30 ng / mL in yet another example for at least about 10 days, greater than 40 ng / mL in yet another example for at least about 10 days, greater than 50 ng / mL in yet another example for at least about 10 days, greater than 60 ng / mL in yet another example for at least about 10 days, and greater than 70 ng / mL in yet another example for at least about 10 days. , in yet another example, it remains greater than 80 ng / mL for at least about 10 days, in yet another example, it remains greater than 90 ng / mL for at least about 10 days, in yet another example, it remains greater than 100 ng / mL for at least about 10 days, in one example, it remains greater than 10 ng / mL for at least about 20 days, in another example, it remains greater than 20 ng / mL for at least about 20 days, in yet another example, it remains greater than 30 ng / mL for at least about 20 days, in yet another example, it remains greater than 40 ng / mL for at least about 20 days, and in yet another example, it remains greater than 50 ng / mL In one example, the concentration of 10 ng / mL is maintained at least about 20 days, in another ... at least about 30 days, in yet another example, it remains greater than 40 ng / mL for at least about 30 days, in yet another example, it remains greater than 50 ng / mL for at least about 30 days, in yet another example, it remains greater than 60 ng / mL for at least about 30 days, in yet another example, it remains greater than 70 ng / mL for at least about 30 days, in yet another example, it remains greater than 80 ng / mL for at least about 30 days, in yet another example, it remains greater than 90 ng / mL for at least about 30 days, in yet another example, it remains greater than 100 ng / mL for at least about 30 days,In one example, it remains greater than 10 ng / mL for at least about 40 days, in another example, it remains greater than 20 ng / mL for at least about 40 days, in yet another example, it remains greater than 30 ng / mL for at least about 40 days, in yet another example, it remains greater than 40 ng / mL for at least about 40 days, in yet another example, it remains greater than 50 ng / mL for at least about 40 days, in yet another example, it remains greater than 60 ng / mL for at least about 40 days, in yet another example, it remains greater than 70 ng / mL for at least about 40 days, in yet another example, it remains greater than 80 ng / mL for at least about 40 days, in yet another example, it remains greater than 90 ng / mL for at least about 40 days, in yet another example, it remains greater than 1 ...20 ng / mL for at least about 40 days, in yet another example, it remains greater than 130 ng / mL for at least about 40 days, in yet another example, it remains greater than 140 ng / mL for at least about 40 days, in yet another example, it remains greater than 150 ng / mL for at least about 40 days, in yet another example, it remains greater than 160 ng / mL for at least about 40 days In one example, the concentration of 100 ng / mL is maintained at least about 40 days, in one example, it is maintained at least about 10 ng / mL for at least about 50 days, in another example, it is maintained at least about 20 ng / mL for at least about 50 days, in yet another example, it is maintained at least about 30 ng / mL for at least about 50 days, in yet another example, it is maintained at least about 40 ng / mL for at least about 50 days, in yet another example, it is maintained at least about 50 ng / mL for at least about 50 days, in yet another example, it is maintained at least about 60 ng / mL for at least about 50 days, in yet another example, it is maintained at least about 70 ng / mL for at least about 50 days, in yet another example, it is maintained at least about 80 ng / mL for at least about 50 days, in yet another example, it is maintained at least about 90 ng / mL for at least about 50 days, in yet another example, it is maintained at least about 90 ng / mL for at least about 50 days. In one example, the concentration of 10 ng / mL is maintained at least about 50 days, in another example, it is maintained at more than 100 ng / mL for at least about 50 days, in one example, it is maintained at more than 10 ng / mL for at least about 60 days, in another example, it is maintained at more than 20 ng / mL for at least about 60 days, in another example, it is maintained at more than 30 ng / mL for at least about 60 days, in another example, it is maintained at more than 40 ng / mL for at least about 60 days, in another example, it is maintained at more than 50 ng / mL for at least about 60 days, in another example, it is maintained at more than 60 ng / mL for at least about 60 days, in another example, it is maintained at more than 70 ng / mL for at least about 60 days, and in another example, it is maintained at more than 80 ng / mL. for at least about 60 days, in yet another example it remains above 90 ng / mL for at least about 60 days, in yet another example it remains above 100 ng / mL for at least about 60 days, in one example it remains above 10 ng / mL for at least about 60 days or more, in another example it remains above 20 ng / mL for at least about 60 days or more, in yet another example it remains above 30 ng / mL for at least about 60 days or more, in yet another example it remains above 40 ng / mL for at least about 60 days or more, in yet another example it remains above 50 ng / mL for at least about 60 days or more, in yet another example it remains above 60 ng / mL for at least about 60 days or more,In yet another example, the neuroactive steroid can maintain a plasma concentration of greater than 20 ng / mL for at least about 30 days. In yet another example, the neuroactive steroid can maintain a plasma concentration of greater than 20 ng / mL for at least about 30 days.

[0045] In some cases, the pharmaceutical composition releases less than about 5%-50% of the neuroactive steroid within about 1 hour of intramuscular or subcutaneous injection of a single dose of the pharmaceutical composition. In particular, within about 1 hour of administering a single dose of the pharmaceutical composition to a subject by intramuscular or subcutaneous injection, the pharmaceutical composition may release less than about 5%-50% of the neuroactive steroid to the subject's plasma in one example, 10%-50% in another example, 15%-50% in yet another example, 20%-50% in yet another example, 25%-50% in yet another example, 30%-50% in yet another example, 40%-50% in yet another example, and 45%-50% in yet another example. The percentage released is based on the measured plasma concentration of the neuroactive steroid and the total amount of the neuroactive steroid in the single dose of the pharmaceutical composition administered to the subject.

[0046] In some cases, a pharmaceutical composition may have a relative bioavailability (bioavailability) of about 2% to 50% 24 hours after a single dose injected intramuscularly or subcutaneously, compared to the same dose administered intravenously. IM / SC / Bioavailability IV ). In some cases, the relative bioavailability can be about 2% to about 50%. In some cases, the relative bioavailability can be at least about 2%. In some cases, the relative bioavailability can be up to about 50%. In some cases, the relative bioavailability can be about 2% to about 5%, about 2% to about 10%, about 2% to about 20%, about 2% to about 30%, about 2% to about 40%, about 2% to about 50%, about 5% to about 10%, about 5% to about 20%, about 5% to about 30%, about 5% to about 40%, about 5% to about 50%, about 10% to about 20%, about 10% to about 30%, about 10% to about 40%, about 10% to about 50%, about 20% to about 30%, about 20% to about 40%, about 20% to about 50%, about 30% to about 40%, about 30% to about 50%, or about 40% to about 50%. In some cases, the relative bioavailability can be about 2%, about 5%, about 10%, about 20%, about 30%, about 40%, or about 50%.

[0047] In some cases, the disclosed pharmaceutical compositions may include particles comprising at least one neuroactive steroid and one or more pharmaceutically acceptable excipients, wherein the neuroactive steroid is gamma-aminobutyric acid type A (GABA A ) receptor positive modulator; wherein the particles comprise large particles having a particle size in the range of about 1.5 μm to about 15 μm and small particles having a particle size in the range of about 0.2 μm to about 1.5 μm; and wherein about 0.01% to about 50% of the particles are small particles and about 50% to about 99.99% of the particles are large particles, the percentages being based on the total weight of the particles. In any of the embodiments or examples of the pharmaceutical composition, the particles can be stabilized particles disclosed herein.

[0048] In some cases, the disclosed pharmaceutical compositions may include a pharmaceutically effective amount of a neuroactive steroid, wherein the neuroactive steroid is a gamma-aminobutyric acid type A (GABA A ) receptor positive modulator; wherein after a single dose of the pharmaceutical composition is administered to a subject by intravenous (IV) injection, intramuscular (IM) injection, subcutaneous (SC) injection, or a combination thereof, the neuroactive steroid reaches a maximum plasma concentration (C max ) and remain greater than C max wherein the pharmaceutical composition comprises particles of the neuroactive steroid; wherein the particles comprise large particles having a particle size in the range of about 1.5 μm to about 15 μm and small particles having a particle size in the range of about 0.2 μm to about 1.5 μm; and wherein about 0.01% to about 50% of the particles are small particles and about 50% to 99.99% of the particles are large particles, the percentages being based on the total weight of the particles.

[0049] In some cases, the maximum plasma concentration (C max ).

[0050] In some cases, the particles may have a D50 in the range of 1.2 μm to about 6.0 μm. The D50 may be 1.2 μm in one example, 1.3 μm in another example, 1.4 μm in yet another example, 1.5 μm in yet another example, 1.6 μm in yet another example, 1.7 μm in yet another example, 1.8 μm in yet another example, 1.9 μm in yet another example, 2.0 μm in yet another example, 2.2 μm in yet another example, 2.4 μm in yet another example. In another example, the thickness of the optical fiber may be 2.6 μm, in another example, it may be 2.8 μm, in another example, it may be 3.0 μm, in another example, it may be 3.5 μm, in another example, it may be 4.0 μm, in another example, it may be 4.5 μm, in another example, it may be 5.0 μm, in another example, it may be 5.5 μm, in another example, it may be 6.0 μm, or in another example, it may be any value in the range of 1.2 μm to 6.0 μm.

[0051] The neuroactive steroid of the disclosed pharmaceutical composition can include tetrahydrodeoxycorticosterone (THDOC), androstane, androstane 3α-androstanediol, cholestane cholesterol, pregnane, pregnenolone (ethanolone), allopregnanolone, allopregnanolone, ganaxolone, zulanolone (SAGE-217), or a combination thereof. For example, the neuroactive steroid can be allopregnanolone.

[0052] In some cases, the large particles may have an average particle size in a range of 2.0 to 6.0 μm in one example, 3.0 to 5.0 μm in another example, 0.4 to 1.3 μm in yet another example, and 0.5 to 0.9 μm in another example.

[0053] The pharmaceutical composition may also include one or more pharmaceutically acceptable excipients. Pharmaceutically acceptable excipients may include surfactants, emulsifiers, fillers, carriers, isotonic agents, dispersants, viscosity modifiers, resuspending agents, buffers or combinations thereof. Pharmaceutical excipients generally do not have the characteristics of a drug or a pharmaceutically active ingredient, and the ingredient is also referred to as an active pharmaceutical ingredient (API), and is generally used to simplify the encapsulation of a production process or active ingredient, or for delivering API to a patient or other subject. Pharmaceutically acceptable excipients or inactive ingredients from the inactive ingredient database (Inactive Ingredients Database) (https: / / www.fda.gov / drugs / drug-approvals-and-databases / inactive-ingredients-database-download) available from US FDA may be suitable. Some GRAS foods available from the US FDA's Generally Recognized as Safe Substances (SCOGS) database (https: / / www.fda.gov / food / generally-recognized-safe-gras / gras-substances-scogs-database) may also be suitable.

[0054] In some cases, pharmaceutically acceptable excipients may include acacia, animal oil, benzyl alcohol, benzyl benzoate, calcium stearate, carbomer, cetearyl alcohol, cetyl alcohol, cholesterol, cyclodextrin, dextrose, diethanolamine, emulsifying wax, ethylene glycol palmitostearate, glycerol, glyceryl monostearate, glyceryl stearate, monoolein, monostearin, hydrate, histidine, hydrochloric acid, hydroxypropylcellulose, hydroxypropyl-β-cyclodextrin (HPBCD), hydroxypropylmethylcellulose (hydroxypropyl methylcellulose (HPMC)), lanolin, lanolin alcohol, lecithin, medium chain triglycerides, metal soaps, methylcellulose, mineral oil, sodium dihydrogen phosphate, monoethanolamine, oleic acid, polyethylene glycol (PEG 3350, PEG 4000, PEG6000), polyoxyethylene-polyoxypropylene copolymer (poloxamer), polyoxyethylene alkyl ether, polyoxyethylene castor oil, polyoxyethylene castor oil derivative, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene stearate, polysorbate, polyoxyethylene (20) sorbitan monolaurate (Tween 20, polysorbate 20), polyoxyethylene (20) sorbitan monooleate (Tween 80, polysorbate 80), povidone, propylene glycol alginate, saline, sodium chloride, sodium citrate, sodium citrate dihydrate, sodium hydroxide, sodium lauryl sulfate, sodium dihydrogen phosphate, disodium hydrogen phosphate, sorbitan ester, stearic acid, stearyl alcohol, sunflower oil, tragacanth gum, triethanolamine, vegetable oil, water, xanthan gum or a combination thereof.

[0055] In some cases, the pharmaceutically acceptable excipients may include dextrose, glycerol, histidine, hydrochloric acid, hydroxypropylcellulose, hydroxypropyl-β-cyclodextrin (HPBCD), hydroxypropyl methylcellulose (hydroxypropyl methylcellulose (HPMC)), polyoxyethylene (20) sorbitan monolaurate (Tween 20, polysorbate 20), polyethylene glycol (PEG 3350, PEG 4000, PEG 6000), polyoxyethylene-polyoxypropylene copolymer (Poloxamer 188, Poloxamer 407), polyoxyethylene (20) sorbitan monooleate (Tween 80, polysorbate 80), saline, sodium chloride, sodium citrate, sodium citrate dihydrate, sodium lauryl sulfate, sodium dihydrogen phosphate, sodium hydrogen phosphate, or a combination thereof.

[0056] The pharmaceutical composition may be suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or infusion). Depending on the route of administration, the active ingredient may be coated in a material to protect it from acid action and other natural conditions that may inactivate it. As used herein, the phrase "parenteral administration" means a mode of administration other than enteral and topical administration, usually by injection, and includes but is not limited to intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion. Alternatively, the pharmaceutical composition may be administered by a non-parenteral route, such as a topical, epidermal or mucosal administration route, for example, intranasal, oral, vaginal, rectal, sublingual or topical administration. The pharmaceutical composition may be in the form of a sterile aqueous solution or a dispersant. The pharmaceutical composition may also be suitable for microemulsions, liposomes or other ordered structures of high drug concentrations.

[0057] The pharmaceutical composition may comprise a population of particles comprising a neuroactive steroid, wherein the particles have an average particle size of about 0.1-50 μm. In some cases, the particles may have an average particle size of about 0.1 μm to about 50 μm. In some cases, the particles may have an average particle size of at least about 0.1 μm. In some cases, the particles may have an average particle size of up to about 50 μm. In some cases, the particles may have an average particle size of about 0.1 μm to about 0.2 μm, about 0.1 μm to about 0.5 μm, about 0.1 μm to about 1 μm, about 0.1 μm to about 2 μm, about 0.1 μm to about 5 μm, about 0.1 μm to about 10 μm, about 0.1 μm to about 20 μm, about 0.1 μm to about 30 μm, about 0.1 μm to about 40 μm, about 0.1 μm to about 50 μm, about 0.2 μm to about 0.5 μm, about 0.2 μm to about 1 μm, about 0 .2μm to about 2μm, about 0.2μm to about 5μm, about 0.2μm to about 10μm, about 0.2μm to about 20μm, about 0.2μm to about 30μm, about 0.2μm to about 40μm, about 0.2μm to about 50μm, about 0.5μm to about 1μm, about 0.5μm to about 2μm, about 0.5μm to about 5μm, about 0.5μm to about 10μm, about 0.5μm to about 20μm, about 0.5μm to about 30μm, about 0.5μm to about about 40 μm, about 0.5 μm to about 50 μm, about 1 μm to about 2 μm, about 1 μm to about 5 μm, about 1 μm to about 10 μm, about 1 μm to about 20 μm, about 1 μm to about 30 μm, about 1 μm to about 40 μm, about 1 μm to about 50 μm, about 2 μm to about 5 μm, about 2 μm to about 10 μm, about 2 μm to about 20 μm, about 2 μm to about 30 μm, about 2 μm to about 40 μm, about 2 μm to about 50 μm, about 5 μm to about 10 μm , about 5 μm to about 20 μm, about 5 μm to about 30 μm, about 5 μm to about 40 μm, about 5 μm to about 50 μm, about 10 μm to about 20 μm, about 10 μm to about 30 μm, about 10 μm to about 40 μm, about 10 μm to about 50 μm, about 20 μm to about 30 μm, about 20 μm to about 40 μm, about 20 μm to about 50 μm, about 30 μm to about 40 μm, about 30 μm to about 50 μm, or about 40 μm to about 50 μm. In some cases, the particles may have an average particle size of about 0.1 μm, about 0.2 μm, about 0.5 μm, about 1 μm, about 2 μm, about 5 μm, about 10 μm, about 20 μm, about 30 μm, about 40 μm, or about 50 μm. The particles can have an average particle size of about 1.5-15 μm in one example, about 3-5 μm in another example, about 0.2-1.5 μm in yet another example, and about 0.5-0.9 μm in yet another example.

[0058] The pharmaceutical composition may comprise at least 50%, 60%, 70%, 80% or 90% by weight of particles having a particle size of about 0.2-15 μm. The pharmaceutical composition may comprise about 0.01% to 50% by weight of particles having an average particle size of about 1.5-15 μm and about 50% to 99.99% by weight of particles having an average particle size of about 0.2-1.5 μm.

[0059] The neuroactive steroid of the pharmaceutical composition may include allopregnanolone, ganaxolone, zulanolone (SAGE-217), or a combination thereof.

[0060] In some cases, the neuroactive steroid may include allopregnanolone. The pharmaceutical composition may include allopregnanolone in a range of 5 mg / mL to 800 mg / mL or any specific range of the neuroactive steroid disclosed above or below. The pharmaceutical composition may be a parenteral injection suspension comprising allopregnanolone. In some cases, the pharmaceutical composition may contain large particles having a particle size in a range of about 1.5 μm to about 15 μm and small particles having a particle size in a range of about 0.2 μm to about 1.5 μm. The pharmaceutical composition comprising allopregnanolone may comprise particles having about 0.01% to about 50% of small particles and about 50% to about 99.99% of large particles, the percentages being based on the total weight of the particles. Such pharmaceutical compositions comprising allopregnanolone may comprise small particles in the range of 0.01% to 50% in one example, 10% to 50% in another example, 15% to 50% in yet another example, 20% to 50% in yet another example, 25% to 50% in yet another example, 30% to 50% in yet another example, 40% to 50% in yet another example, and 45% to 50% in yet another example; and large particles in the range of 50% to 90% in one example, 55% to 90% in another example, 60% to 90% in yet another example, 65% to 90% in yet another example, 70% to 90% in yet another example, 75% to 90% in yet another example, 80% to 90% in yet another example, and 85% to 90% in yet another example. In a particular example, the pharmaceutical composition may comprise about 10% to about 50% small particles and about 50% to about 90% large particles, the percentages being based on the total weight of the particles. In an even further example, the pharmaceutical composition may comprise about 0.1% to about 1% small particles and about 90% to about 99.9% large particles, the percentages being based on the total weight of the particles.

[0061] The neuroactive steroid may include ganaxolone, and the pharmaceutical composition may include ganaxolone in the range of 100 mg / mL to 800 mg / mL, or any specific range of the neuroactive steroid disclosed herein. The pharmaceutical composition may be a parenteral injection suspension comprising ganaxolone. The pharmaceutical composition comprising ganaxolone may include about 0.01% to about 50% small particles and about 50% to about 99.99% large particles, the percentages being based on the total weight of the particles. Such pharmaceutical compositions comprising ganaxolone may comprise small particles in the range of 0.01% to 50% in one example, 0.1% to 50% in another example, 1.0% to 50% in yet another example, 2.0% to 50% in yet another example, 4.0% to 50% in yet another example, 6.0% to 50% in yet another example, 8.0% to 50% in yet another example, 10% to 50% in one example, 15% to 50% in another example, 20% to 50% in yet another example, 25% to 50% in yet another example, and 25% to 50% in yet another example. In one example, 30% to 50%, in another example, 40% to 50%, and in another example, 45% to 50%; and in one example, 50% to 99.99% large particles are included, in another example, 55% to 99.99%, in another example, 60% to 99.99%, in another example, 65% to 99.99%, in another example, 70% to 99.99%, in another example, 75% to 99.99%, in another example, 80% to 99.99%, and in another example, 85% to 99.99%. In a specific example, the pharmaceutical composition may contain about 0.01% to about 10% small particles and about 90% to about 99.99% large particles, the percentages being based on the total weight of the particles.

[0062] A schematic diagram of the particle size distribution is shown in Figure 1A-Figure 1D In one example, the pharmaceutical composition may contain a very small amount, such as in the range of 0.01% to 1%, of small particles and mainly contain large particles ( Figure 1A In this example, D50 can be very close to the average particle size of large particles. In another example, the pharmaceutical composition can contain some amount of small particles, such as in the range of 1% to 5%, and 95% to 99% large particles ( Figure 1B In yet another example, the pharmaceutical composition comprises an increasing amount of small particles such as 5% to 10% and 90% to 95% large particles ( Figure 1C In yet another example, the pharmaceutical composition comprises similar amounts of small particles, such as 10% to 40%, and large particles, such as 60% to 90%. Figure 1D ).

[0063] The pharmaceutical composition may be substantially free of cyclodextrin. In an example, the pharmaceutical composition is substantially free of cyclodextrin means that the pharmaceutical composition contains 0% to 0.1%, 0% to 0.01%, 0% to 0.001%, 0% to 0.0001% or less cyclodextrin, all percentages are based on the total weight of the pharmaceutical composition.

[0064] The pharmaceutical composition may be substantially free of sulfobutyl ether β-cyclodextrin. In an example, the pharmaceutical composition being substantially free of sulfobutyl ether β-cyclodextrin means that the pharmaceutical composition comprises 0% to 0.1%, 0% to 0.01%, 0% to 0.001%, 0% to 0.0001% or less sulfobutyl ether β-cyclodextrin, all percentages being based on the total weight of the pharmaceutical composition.

[0065] In other examples, the pharmaceutical composition may be a liquid suspension for intramuscular (IM) or subcutaneous (SC) injection.

[0066] Also disclosed herein is a method for producing a pharmaceutical composition disclosed herein. In some cases, the method may include: a) mixing a composition comprising a neuroactive steroid with one or more pharmaceutically acceptable excipients; and b) grinding the composition to produce a particle population, thereby producing the pharmaceutical composition. In some cases, the method may include: a) grinding a composition comprising a neuroactive steroid to produce a particle population; and b) mixing the composition with one or more pharmaceutically acceptable excipients to produce the pharmaceutical composition. In some cases, the method includes crystallizing allopregnanolone polymorph A from one or more solvents selected from the group consisting of: dichloromethane (DCM), tetrahydrofuran (THF), ethyl acetate (EtOAc), dimethyl sulfoxide (DMSO), toluene, 2-propanol: water (9: 1), methanol (MeOH), 2-propanol (IPA), methyl tert-butyl ether (MTBE), isopropyl ether (IPE), acetonitrile (MeCN) and water. In some cases, one or more solvents do not include acetonitrile. In some cases, the method further comprises a) mixing allopregnanolone polymorph A with one or more pharmaceutically acceptable excipients to form a composition; and b) grinding the composition to produce a population of particles of the pharmaceutical composition. In some cases, the method further comprises a) grinding the composition comprising allopregnanolone polymorph A to produce a population of particles; and b) mixing the composition with one or more pharmaceutically acceptable excipients to produce the pharmaceutical composition. In some cases, the pharmaceutical composition is a liquid suspension for intramuscular or subcutaneous injection.

[0067] In some cases, disclosed herein is a method for producing a pharmaceutical composition comprising particles, the method comprising: producing a particle mixture comprising at least one neuroactive steroid and one or more pharmaceutically acceptable excipients; grinding a first portion of the particle mixture to produce a large particle mixture, wherein at least 50% of the large particle mixture is large particles having a particle size in the range of about 1.5 μm to about 15 μm, the percentage being based on the total weight of the particle mixture; and producing a pharmaceutical composition comprising particles, the particles comprising about 50% to 99.99% large particles, the percentage being based on the total weight of the particles.

[0068] The neuroactive steroid can be selected from tetrahydrodeoxycorticosterone (THDOC), androstane, androstane 3α-androstanediol, cholestane cholesterol, pregnane, pregnenolone (ethanolone), allopregnanolone, allopregnanolone, ganaxolone, zuranosolone (SAGE-217), or a combination thereof. In one example, the neuroactive steroid is allopregnanolone. In another example, the neuroactive steroid is ganaxolone. In another example, the neuroactive steroid is zuranosolone.

[0069] Commercially available or proprietary neuroactive steroid APIs may be suitable as starting materials for producing the particle mixture. Typically, commercially available neuroactive steroid APIs may have large particle sizes. For example, commercial allopregnanolone may have a particle size of about 7 to 10 μm in diameter. In another example, commercial ganaxolone may have a particle size of about 40 to 50 μm. The milling process may reduce the particles to a range of suitable sizes.

[0070] Typical grinding media such as grinding beads can be used to grind the particles. The grinding beads can have a diameter of 0.1 mm to about 1 mm. In an example, a rotary grinding process using a rotational speed of 300 to 600 rpm can be suitable. The particles can be ground for 10 to 40 minutes, 10 to 40 cycles or the time and cycle sufficient to produce particles of a desired size range. Grinding can be performed in the presence of one or more excipients disclosed herein.

[0071] The large particles may have an average particle size in the range of 1.5 μm to about 15 μm in one example, 1.5 μm to 10 μm in another example, 1.5 μm to 8,000 μm in another example, 1.5 μm to 6.0 μm in another example, and 1.5 μm to 4.5 μm in another example. In other examples, the large particles may have an average particle size in the range of 2.0 to 6.0 μm. In other embodiments, the large particles may have an average particle size in the range of 2.0 to 5.0 μm. In one other example, the large particles may have a particle size of about 2.0 μm to about 4.5 μm.

[0072] The process or method may further include: grinding a second portion of the particle mixture to produce a small particle mixture, wherein the small particle mixture comprises small particles having a particle size in the range of about 0.2 μm to about 1.5 μm. In some cases, the pharmaceutical composition is produced by: mixing the large particle mixture with the small particle mixture to form particles comprising about 50% to 99.99% large particles and 0.01% to 50% small particles, the percentages being based on the total weight of the particles.

[0073] The first part and the second part can be the same or different. In some examples, the first part and the second part are the same, and the particle mixture is configured to include large particles and small particles after grinding. In some other examples, the second part can be a part of the first part and further ground to produce small particles. In some other examples, the first part and the second part are divided by the initial particle mixture and ground separately to produce large particles and small particles, respectively.

[0074] The small particles may have an average particle size in a range of 0.2 μm to about 1.5 μm in one example, 0.2 μm to 1.2 μm in another example, 0.2 μm to 1.0 μm in yet another example, 0.2 μm to 0.8 μm in yet another example, and 0.2 μm to 0.7 μm in yet another example. In other examples, the small particles may have an average particle size in a range of 0.4 to 1.3 μm. In other examples, the small particles may have an average particle size in a range of 0.5 to 0.9 μm. In even further examples, the small particles may have an average particle size of about 0.7 μm.

[0075] Suitable pharmaceutically acceptable excipients can be selected from gum arabic, animal oil, benzyl alcohol, benzyl benzoate, calcium stearate, carbomer, cetearyl alcohol, cetyl alcohol, cholesterol, cyclodextrin, dextrose, diethanolamine, emulsifying wax, ethylene glycol palmitostearate, glycerol, glyceryl monostearate, glyceryl stearate, monoolein, monostearin, histidine, hydrochloric acid, hydrate, hydroxypropylcellulose, hydroxypropyl-β-cyclodextrin (HPBCD), hydroxypropylmethylcellulose (hydroxypropylmethylcellulose (HPMC)), lanolin, lanolin alcohol, lecithin, medium chain triglycerides, metal soaps, methylcellulose, mineral oil, sodium dihydrogen phosphate, monoethanolamine, oleic acid, polyethylene glycol (PEG 3350, PEG4000, PEG 6000), polyoxyethylene-polyoxypropylene copolymer (poloxamers), polyoxyethylene alkyl ethers, polyoxyethylene castor oil, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, polysorbates, polyoxyethylene (20) sorbitan monolaurate (Tween 20, polysorbate 20), polyoxyethylene (20) sorbitan monooleate (Tween 80, polysorbate 80), povidone, propylene glycol alginate, saline, sodium chloride, sodium citrate, sodium citrate dihydrate, sodium hydroxide, sodium lauryl sulfate, sodium dihydrogen phosphate, disodium hydrogen phosphate, sorbitan esters, stearic acid, stearyl alcohol, sunflower oil, tragacanth gum, triethanolamine, vegetable oil, water, xanthan gum, and combinations thereof.

[0076] In some cases, the pharmaceutically acceptable excipient may include dextrose, glycerol, histidine, hydrochloric acid, hydroxypropylcellulose, hydroxypropyl-β-cyclodextrin (HPBCD), hydroxypropyl methylcellulose (hydroxypropyl methylcellulose (HPMC)), polyoxyethylene (20) sorbitan monolaurate (Tween 20, polysorbate 20), polyethylene glycol (PEG 3350, PEG 4000, PEG 6000), polyoxyethylene-polyoxypropylene copolymer (poloxamer 188, poloxamer 407), polyoxyethylene (20) sorbitan monooleate (Tween 80, polysorbate 80), saline, sodium chloride, sodium citrate, sodium citrate dihydrate, sodium lauryl sulfate, sodium dihydrogen phosphate, disodium hydrogen phosphate, or a combination thereof.

[0077] In some cases, the pharmaceutical composition may be formulated as a parenteral injection suspension and / or suitable for oral administration, intramuscular (IM) injection, subcutaneous (SC) injection, intravenous (IV) injection, or a combination thereof.

[0078] In some cases, the neuroactive steroid may include allopregnanolone, and the pharmaceutical composition may include allopregnanolone in a range of 5 mg / mL to 800 mg / mL or any specific range of the neuroactive steroid disclosed herein, such as 100 mg / mL to 800 mg / mL. The pharmaceutical composition may be formulated as a parenteral injection suspension comprising allopregnanolone. The pharmaceutical composition comprising allopregnanolone may comprise particles having about 0.01% to about 50% small particles and about 50% to about 99.99% large particles, the percentages being based on the total weight of the particles. Such pharmaceutical compositions comprising allopregnanolone can be formulated to contain small particles in the range of 0.01% to 50% in one example, 10% to 50% in another example, 15% to 50% in yet another example, 20% to 50% in yet another example, 25% to 50% in yet another example, 30% to 50% in yet another example, 40% to 50% in yet another example, and 45% to 50% in yet another example; and large particles in the range of 50% to 90% in one example, 55% to 90% in another example, 60% to 90% in yet another example, 65% to 90% in yet another example, 70% to 90% in yet another example, 75% to 90% in yet another example, 80% to 90% in yet another example, and 85% to 90% in yet another example. In a particular example, the pharmaceutical composition may comprise about 10% to about 50% small particles and about 50% to about 90% large particles, the percentages being based on the total weight of the particles. In an even further example, the pharmaceutical composition may be configured to comprise about 0.1% to about 1% small particles and about 90% to about 99.9% large particles, the percentages being based on the total weight of the particles.

[0079] The neuroactive steroid may include ganaxolone, and the pharmaceutical composition may include ganaxolone in the range of 100 mg / mL to 800 mg / mL, or any specific range of the neuroactive steroid disclosed herein. The pharmaceutical composition may be formulated as a parenteral injection suspension comprising ganaxolone. The pharmaceutical composition comprising ganaxolone may be configured to comprise from about 0.01% to about 50% small particles and from about 50% to about 99.99% large particles, the percentages being based on the total weight of the particles. Such pharmaceutical compositions comprising ganaxolone can be formulated to contain small particles in the range of 0.01% to 50% in one example, 0.1% to 50% in another example, 1.0% to 50% in yet another example, 2.0% to 50% in yet another example, 4.0% to 50% in yet another example, 6.0% to 50% in yet another example, 8.0% to 50% in yet another example, 10% to 50% in one example, 15% to 50% in another example, 20% to 50% in yet another example, 25% to 50% in yet another example, and 30% to 50% in yet another example. In yet another example, 30% to 50%, in yet another example, 40% to 50%, and in yet another example, 45% to 50%; and in one example, 50% to 99.99% large particles are included, in another example, 55% to 99.99%, in yet another example, 60% to 99.99%, in yet another example, 65% to 99.99%, in yet another example, 70% to 99.99%, in yet another example, 75% to 99.99%, in yet another example, 80% to 99.99%, and in yet another example, 85% to 99.99%. In a specific example, the pharmaceutical composition may contain about 0.01% to about 10% small particles and about 90% to about 99.99% large particles, the percentages being based on the total weight of the particles. In any of the embodiments or examples of the process or method, the particles can be stabilized particles disclosed herein.

[0080] In some cases, an advantage of a pharmaceutical composition is that it can contain small particles and large particles and can release allopregnanolone, ganaxolone, zulanolone (SAGE-217), or a combination thereof in a controlled manner. Without wishing to be bound by a particular theory or mechanism, applicants believe that small particles can provide an earlier or faster release, while large particles provide a longer or sustained release. By optimizing the ratio of small particles to large particles, an optimized release profile can be achieved for the most preferred treatment regimen for a disease.

[0081] In some cases, another advantage of the disclosed pharmaceutical compositions is that they can be administered to a subject in a shorter administration period due to the optimized release profile, preventing interaction with other drugs such as ZULRESSO. TM The longer injection times associated with currently available drugs.

[0082] Also disclosed herein is a method for treating a disease in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition disclosed herein or a pharmaceutical composition manufactured by the method disclosed herein by intramuscular (IM) injection, subcutaneous (SC) injection, intravenous (IV) injection, or a combination thereof. In some instances, intramuscular (IM) injection or subcutaneous (SC) injection is preferred. In some cases, the method may include: administering to the subject a pharmaceutical composition disclosed herein by intramuscular or subcutaneous injection.

[0083] In some cases, a method of treating a disease in a subject in need thereof is disclosed, the method comprising: administering to the subject a pharmaceutical composition comprising a pharmaceutically effective amount of a neuroactive steroid in a single dose ranging from 0.5 to 10 mg per kilogram of body weight by intramuscular or subcutaneous injection, wherein the neuroactive steroid is gamma-aminobutyric acid type A (GABA A ) receptor positive modulator; and wherein after intramuscular or subcutaneous injection into a subject, the plasma concentration of the neuroactive steroid in the subject reaches a maximum plasma concentration (C max ) and remain greater than C in the subjects max Plasma concentrations of about 5% of the drug persist for at least about 5 days.

[0084] As mentioned above, body weight may refer to the body weight of a subject such as a human patient. Ranges include single doses of 0.5, 10 mg per kilogram of body weight and continuous ranges including every value between 0.5 and 10 mg per kilogram of body weight. For animal subjects, single doses may differ from those mentioned above.

[0085] In some cases, the pharmaceutical composition can be administered to the subject by intramuscular (IM) injection, subcutaneous (SC) injection, intravenous (IV) injection or a combination thereof. The pharmaceutical composition can be administered to the subject in a single injection mode, in a continuous injection mode or a combination thereof. The pharmaceutical composition can be administered to the subject in a time period within the range of 1 second to about 180 minutes. In one example, the pharmaceutical composition can be administered to the subject in a time period within the range of about 1 second to about 180 minutes, in another example, 1 minute to about 180 minutes, in another example, about 5 minutes to about 180 minutes, in another example, about 10 minutes to about 180 minutes, in another example, about 20 minutes to about 180 minutes, in another example, about 40 minutes to about 180 minutes, in another example, about 50 minutes to about 180 minutes, in another example, about 60 minutes to about 180 minutes, or any time value within the range. In other examples, the pharmaceutical composition may be administered to a subject over a period of time ranging from 1 second to about 150 minutes, 1 second to about 100 minutes, 1 second to about 80 minutes, 1 second to about 60 minutes, 1 second to about 30 minutes, 1 second to about 10 minutes, 1 second to about 5 minutes, and in yet another example, 1 second to about 1 minute. In a specific example, a single injection completed at one time may be used to administer the pharmaceutical composition to a subject. In other examples, two or more injections may be used to administer the pharmaceutical composition to a subject.

[0086] In some cases, the disease can be selected from anxiety, mood disorders, severe depression, postpartum conditions, Alzheimer's disease, Parkinson's disease, epilepsy, focal epileptic seizures, PCDH19 childhood epilepsy, childhood genetic epilepsy, CDKL5 deficiency (CDD), catamenial epilepsy, infantile spasms, fragile X syndrome, depression, postpartum depression and premenstrual syndrome. In some cases, the disease can be postpartum depression. The subject may have a history of depression. In some cases, the subject may have a history of postpartum depression.

[0087] Also disclosed herein is the use of a composition comprising a neuroactive steroid for the manufacture of a medicament for treating a disease, wherein the composition is a pharmaceutical composition disclosed herein. The disease may be selected from anxiety, mood disorders, major depression, postpartum conditions, Alzheimer's disease, Parkinson's disease, epilepsy, focal epileptic seizures, PCDH19 childhood epilepsy, childhood genetic epilepsy, CDKL5 deficiency (CDD), menstrual epilepsy, infantile spasms, fragile X syndrome, depression, postpartum depression, and premenstrual syndrome. Neuroactive steroids may be selected from tetrahydrodeoxycorticosterone (THDOC), androstane, androstane 3α-androstanediol, cholestane cholesterol, pregnane, pregnane pregnenolone (ethanolide), allopregnanolone, allopregnanolone, ganaxolone, zuranolone (SAGE-217), and combinations thereof.

[0088] In some cases, the composition comprises a neuroactive steroid for use in a method for treating a disease, wherein the neuroactive steroid is gamma-aminobutyric acid type A (GABA A ) receptor positive modulator; and wherein after intramuscular or subcutaneous injection of a single dose of the neuroactive steroid, the plasma concentration of the neuroactive steroid reaches a maximum plasma concentration (C max ) and remain greater than C max The plasma concentration of about 5% of the drug lasts for at least about 5 days. The disease can be selected from anxiety, mood disorders, major depression, postpartum conditions, Alzheimer's disease, Parkinson's disease, epilepsy, focal epileptic seizures, PCDH19 childhood epilepsy, childhood genetic epilepsy, CDKL5 deficiency (CDD), menstrual epilepsy, infantile spasms, fragile X syndrome, depression, postpartum depression and premenstrual syndrome. Neuroactive steroids can be selected from tetrahydrodeoxycorticosterone (THDOC), androstane, androstane 3α-androstanediol, cholestane cholesterol, pregnane, pregnane pregnenolone (ethanorolone), allopregnanolone, allopregnanolone, ganaxolone, zulanolone (SAGE-217) and combinations thereof. In some cases, the composition is a pharmaceutical composition disclosed herein. In some cases, the method is the method disclosed above.

[0089] In some cases, disclosed herein is the use of particles comprising at least one neuroactive steroid and one or more pharmaceutically acceptable excipients for the manufacture of a medicament for treating a disease, wherein the particles comprise large particles having a particle size in the range of about 1.5 μm to about 15 μm and small particles having a particle size in the range of about 0.2 μm to about 1.5 μm; and wherein about 0.01% to about 50% of the particles are small particles and about 50% to 99.99% of the particles are large particles, the percentages being based on the total weight of the particles. The neuroactive steroid may be selected from tetrahydrodeoxycorticosterone (THDOC), androstane, androstane 3α-androstanediol, cholestane cholesterol, pregnane, pregnane pregnenolone (ethanolide), allopregnanolone, allopregnanolone, ganaxolone, zuranolone (SAGE-217), and combinations thereof. In some cases, the large particles may have an average particle size in a range of 2.0 to 6.0 μm in one example, 3.0 to 5.0 μm in another example, 0.4 to 1.3 μm in yet another example, and 0.5 to 0.9 μm in yet another example. The particles may be stabilized particles disclosed herein.

[0090] In some cases, pharmaceutically acceptable excipients may include surfactants, emulsifiers, fillers, carriers, isotonic agents, dispersants, viscosity modifiers, resuspending agents, buffers, or combinations thereof. In some cases, pharmaceutically acceptable excipients include gum arabic, animal oils, benzyl alcohol, benzyl benzoate, calcium stearate, carbomer, cetearyl alcohol, cetyl alcohol, cholesterol, cyclodextrin, dextrose, diethanolamine, emulsifying wax, ethylene glycol palmitostearate, glycerol, glyceryl monostearate, glyceryl stearate, monoolein, monostearin, hydrate, histidine, hydrochloric acid, hydroxypropyl cellulose, hydroxypropyl-β-cyclodextrin (HPBCD), hydroxypropyl methylcellulose (hydroxypropyl methylcellulose (HPMC)), lanolin, lanolin alcohol, lecithin, medium chain triglycerides, metal soaps, methylcellulose, mineral oil, sodium dihydrogen phosphate, monoethanolamine, oleic acid, polyethylene glycol (PEG 3350, PEG 4000, PEG 6000), polyoxyethylene-polyoxypropylene copolymer (poloxamers), polyoxyethylene alkyl ethers, polyoxyethylene castor oil, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, polysorbates, polyoxyethylene (20) sorbitan monolaurate (Tween 20, polysorbate 20), polyoxyethylene (20) sorbitan monooleate (Tween 80, polysorbate 80), povidone, propylene glycol alginate, saline, sodium chloride, sodium citrate, sodium citrate dihydrate, sodium hydroxide, sodium lauryl sulfate, sodium dihydrogen phosphate, disodium hydrogen phosphate, sorbitan esters, stearic acid, stearyl alcohol, sunflower oil, tragacanth gum, triethanolamine, vegetable oil, water, xanthan gum or a combination thereof.

[0091] In some cases, pharmaceutically acceptable excipients may include dextrose, glycerol, histidine, hydrochloric acid, hydroxypropylcellulose, hydroxypropyl-β-cyclodextrin (HPBCD), hydroxypropylmethylcellulose (hydroxypropylmethylcellulose (HPMC)), polyoxyethylene (20) sorbitan monolaurate (Tween 20, polysorbate 20), polyethylene glycol (PEG 3350, PEG 4000, PEG 6000), polyoxyethylene-polyoxypropylene copolymer (poloxamer 188, poloxamer 407), polyoxyethylene (20) sorbitan monooleate (Tween 80, polysorbate 80), saline, sodium chloride, sodium citrate, sodium citrate dihydrate, sodium lauryl sulfate, sodium dihydrogen phosphate, sodium dihydrogen phosphate, or a combination thereof. In some cases, the pharmaceutical composition is a parenteral injection suspension.

[0092] In some cases, the neuroactive steroid can include allopregnanolone, and the pharmaceutical composition comprises allopregnanolone in the range of 80 mg / mL to 400 mg / mL. In some cases, the neuroactive steroid can include ganaxolone, and the pharmaceutical composition comprises ganaxolone in the range of 80 mg / mL to 400 mg / mL.

[0093] In some cases, the pharmaceutical composition may comprise about 10% to about 50% small particles and about 50% to about 90% large particles, the percentages being based on the total weight of the particles. In some cases, the pharmaceutical composition may comprise about 0.01% to about 50% small particles and about 50% to about 99.99% large particles, the percentages being based on the total weight of the particles.

[0094] In some cases, the disease can be selected from anxiety, mood disorders, major depressive disorder, postpartum disorder, Alzheimer's disease, Parkinson's disease, epilepsy, focal seizures, PCDH19 childhood epilepsy, childhood genetic epilepsy, CDKL5 deficiency (CDD), catamenial epilepsy, infantile spasms, fragile X syndrome, depression, postpartum depression and premenstrual syndrome.

[0095] Also disclosed is a method for producing a pharmaceutical composition that releases at least one neuroactive steroid comprising allopregnanolone, ganaxolone, zulanolone (SAGE-217), or a combination thereof in a controlled manner. The method comprises: producing large particles having a particle size in the range of about 1.5 μm to about 15 μm and small particles having a particle size in the range of about 0.2 μm to about 1.5 μm; mixing the small particles with the large particles to produce particles, wherein about 0.01% to about 50% of the particles are small particles and about 50% to 99.99% of the particles are large particles, the percentages being based on the total weight of the particles; and producing a pharmaceutical composition comprising the particles by adjusting the ratio of the small particles to the large particles so that the pharmaceutical composition is configured to release the neuroactive steroid in the subject within 0.1 to 1 hour after administration to a subject in need thereof, and continues to release the neuroactive steroid in the subject for a period of time in the range of 10 hours to about 200 hours after administration to the subject.

[0096] Crystalline forms of allopregnanolone

[0097] Also disclosed is a pharmaceutical composition comprising allopregnanolone polymorph A, characterized in that it has at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 of the peaks located at: 7.25, 8.88, 11.46, 14.50, 14.78, 17.77, 18.15, 18.32, 18.61 and 19.99 ± 0.1 ° 2θ in an X-ray powder diffraction (XRPD) diffraction pattern.

[0098] In some cases, the pharmaceutical composition is a liquid suspension. In some cases, the pharmaceutical composition is for intramuscular or subcutaneous injection. In some cases, the liquid suspension comprises allopregnanolone polymorph A. In some cases, allopregnanolone polymorph A has a chemical purity of greater than 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% (w / w). In some cases, the chemical purity is quantified by HPLC. In some cases, allopregnanolone polymorph A has a melting point of about 170°C-180°C. In some cases, allopregnanolone polymorph A has a melting point of about 174°C.

[0099] In some cases, allopregnanolone polymorph A is crystallized from one or more solvents selected from the group consisting of dichloromethane (DCM), tetrahydrofuran (THF), ethyl acetate (EtOAc), dimethyl sulfoxide (DMSO), toluene, 2-propanol: water (9: 1), methanol (MeOH), 2-propanol (IPA), methyl tert-butyl ether (MTBE), isopropyl ether (IPE), acetonitrile (MeCN) and water. In some cases, the one or more solvents do not contain acetonitrile.

[0100] Example

[0101] The present invention is further defined in the following examples. It should be understood that while these examples indicate preferred embodiments of the present invention, they are given by way of illustration only. Based on the above discussion and these examples, those skilled in the art can determine the essential characteristics of the present invention, and without departing from its spirit and scope, various changes and adjustments can be made to the present invention to make it suitable for various uses and conditions.

[0102] Example 1: Allopregnanolone suspension

[0103] Buy allopregnanolone (APO) in the form of an active pharmaceutical ingredient (API) from a supplier Figure 2A ). The size of commercially available allopregnanolone items is about 7 to 8 μm.

[0104] Commercially available allopregnanolone was milled in the presence of water, saline, dextrose, HPMC, TWEEN 80, poloxamer 407 and glycerol using a rotation speed of 300 to 500 rpm for about 20 to 30 minutes. Depending on the desired particle size, 1-5 cycles of milling were performed. The milling media used were beads having a diameter of 0.1 to 1.0 mm.

[0105] By controlling the grinding parameters, two groups of particle sizes were selected. One group was small particles with an average particle size of about 0.7 μm ( Figure 2B ), and the other group is large particles with an average particle size of about 4.0 μm ( Figure 2C ).

[0106] Example 2: Pharmacokinetics (PK) of Allopregnanolone Compositions in Rats

[0107] Suspensions of 0.7 μm particles and 4.0 μm particles were injected into rats at a dose of 25 mg / kg allopregnanolone by intramuscular (IM) injection. Comparative sex pregnanolone solution was injected at a dose of 12.5 mg / kg by intramuscular (IM) injection or 1 mg / kg by intravenous (IV) injection for comparison. Plasma allopregnanolone concentrations were measured at the indicated time points. Data are shown in Figure 2D-Figure 2E The PK of the solution is adjusted to have a proportional dose.

[0108] Example 3: Injectable Allopregnanolone Pharmaceutical Composition

[0109] A first allopregnanolone composition was produced using the suspension of 0.7 μm particles prepared above to have a desired pharmacokinetic profile.

[0110] A second allopregnanolone composition was produced by mixing the suspension of 0.7 μm particles prepared above with the suspension of 4.0 μm particles. The composition was adjusted to have about 10% 0.7 μm particles and about 90% 4.0 μm particles to have the desired pharmacokinetic profile.

[0111] A third allopregnanolone composition was produced by mixing the suspension of 0.7 μm particles prepared above with the suspension of 4.0 μm particles. The composition was adjusted to have about 30% 0.7 μm particles and about 70% 4.0 μm particles to have the desired pharmacokinetic profile.

[0112] The fourth allopregnanolone composition was produced by mixing the suspension of 0.7 μm particles prepared above with the suspension of 4.0 μm particles. The composition was adjusted to have about 40% 0.7 μm particles and about 60% 4.0 μm particles to have the desired pharmacokinetic profile.

[0113] The fifth allopregnanolone composition was produced by mixing the suspension of 0.7 μm particles prepared above with the suspension of 4.0 μm particles. The composition was adjusted to have about 50% 0.7 μm particles and about 50% 4.0 μm particles to have the desired pharmacokinetic profile.

[0114] A suspension of 4 μm particles prepared above was used to generate a sixth allopregnanolone composition to have a desired pharmacokinetic profile.

[0115] Example 4: Ganaxolone Suspension

[0116] Purchase ganaxolone in the form of an active pharmaceutical ingredient (API) from a supplier Figure 3A ). The size of commercially available ganaxolone particles is approximately 47 μm.

[0117] Commercially available ganaxolone was milled in the presence of water, saline, 1 mg / mL TWEEN 80, and 5 mg / mL HPMC using a rotation speed of about 200 rpm for about 20 minutes. Three cycles of milling were performed. The milling media used were beads having a diameter of 1.0 mm.

[0118] The ground particles have less than 1% of the particle size less than 1.5 μm, which is about 4.1 μm ( Figure 3B ) and about 3.6μm( Figure 3C Particles having an average particle size of about 1.0 μm were also produced.

[0119] Example 5: Pharmacokinetics (PK) of Ganaxolone Compositions in Rats

[0120] Suspensions with 1 μm and 4.1 μm particles were injected into rats at a dose of 25 mg / kg ganaxolone by intramuscular (IM) injection, respectively. Comparative ganaxolone solutions were injected at a dose of 12.5 mg / kg by intramuscular (IM) injection or at 1 mg / kg by intravenous (IV) injection for comparison. Plasma ganaxolone concentrations were measured at designated time points. Data are shown in Figure 3D and Figure 3E The PK of the solution is adjusted to have a proportional dose.

[0121] Example 6: Injectable Ganaxolone Pharmaceutical Compositions

[0122] A first ganaxolone composition was produced using the suspension of 1 μm particles prepared above to have a desired pharmacokinetic profile.

[0123] A second ganaxolone composition was produced by mixing the suspension of 1 μm particles prepared above with the suspension of 4.1 μm particles. The composition was adjusted to have about 10% 1 μm particles and about 90% 4.1 μm particles to have a desired pharmacokinetic profile.

[0124] A third ganaxolone composition was produced by mixing the suspension of 1 μm particles prepared above with the suspension of 4.1 μm particles. The composition was adjusted to have about 30% 1 μm particles and about 70% 4.1 μm particles to have a desired pharmacokinetic profile.

[0125] A fourth ganaxolone composition is produced by mixing the suspension of 1 μm particles prepared above with the suspension of 4.1 μm particles. The composition is adjusted to have about 40% 1 μm particles and about 60% 4.1 μm particles to have a desired pharmacokinetic profile.

[0126] A fifth ganaxolone composition is produced by mixing the suspension of 1 μm particles prepared above with the suspension of 4.1 μm particles. The composition is adjusted to have about 50% 1 μm particles and about 50% 4.1 μm particles to have a desired pharmacokinetic profile.

[0127] A sixth ganaxolone composition was produced using the suspension of 4.1 μm particles prepared above to have a desired pharmacokinetic profile.

[0128] Example 7: Allopregnanolone crystal screening

[0129] Allopregnanolone was purchased from a supplier and slowly ground prior to distribution. Allopregnanolone samples were analyzed by the following analytical techniques: FT-Raman Spectroscopy, FT-IR Spectroscopy, Differential Calorimetry (DSC), Thermogravimetric Analysis (TGA-IR), Polarized Light Microscopy (PLM), and Powder X-ray Diffraction (PXRD). The sample was determined to be a white crystalline powder consisting of irregular particles with a wide variety of sizes, including larger brittle pieces. DSC analysis showed a melting endotherm at 174°C (ΔH=101 J / g). TGA analysis showed negligible (<0.1%) weight loss between 25°C-175°C, indicating that the material was a non-solvate.

[0130] The solubility of the supplied allopregnanolone was determined by visually observing the dissolution in various solvents at room temperature (about 22° C.) and 40° C. Aliquots of solvent were added to a fixed amount of allopregnanolone (about 10 mg) at room temperature until the dissolution point or a maximum volume of 1.8 mL was reached. All samples were then heated to 40° C. for 1 hour and observed for dissolution. As shown in Table 1, at room temperature, allopregnanolone showed low solubility in water (<6 mg / mL), moderate solubility in MeCN, IPE, MTBE, IPA, MeOH, a mixture of IPA: water (9:1, v:v), toluene, DMSO, EtOAc (6-52 mg / mL), and high solubility in THF and DCM (>96 mg / mL).

[0131] Table 1 - Solubility of allopregnanolone at room temperature and 40°C

[0132]

[0133] Crystallization experiments were conducted in three models, including 1) temperature cycling aging of the allopregnanolone slurry at temperatures between 40°C and 5°C for two days (TC) (n=48); 2) heating the slurry to 40°C followed by hot filtration, followed by storage of the allopregnanolone solution at 4°C for up to two days (RC) (n=48); 3) evaporation of the allopregnanolone solution under ambient conditions for up to 7 days (EV) (n=48). A total of 48 solvent systems were included in the crystal screening. Each solvent was utilized in the form of a pure mixture and a binary mixture to provide a variety of polarities, dielectric constants, dipole moments, and hydrogen bond donor / acceptor properties. Aqueous solvents with various water activities were also included to form hydrates.

[0134] All crystal outputs from the screening were separated and analyzed by FT-Raman spectroscopy. The samples were then grouped according to Raman spectral matching. Representative samples from each group were further analyzed by other techniques (PXRD, DSC, TGA, PLM) as appropriate and as the number of samples permitted. These data were used to support Figure 4 The table shown in the distribution.

[0135] like Figure 4 As shown in FIG, 27 crystalline solids were obtained from TC, 14 crystalline solids were obtained from RC and 28 crystalline solids were obtained from EV crystallization mode, for a total of 69 crystalline solids (shaded). Figure 5 The PXRD overlay pattern of the input allopregnanolone and the representative Form A pattern from the screen is shown. The polymorph of allopregnanolone, Form A, was observed in 68 of the 69 samples that produced solids. The description of Form A is illustrated by batch 103260-TC-01. The DSC onset of the melt / decomposition of batch 103260-TC-01 is 174°C (ΔH=127 J / g). The TGA % weight loss before the melt / decomposition event is <0.1%. Form A is a non-solvate form. Characteristic data for Form A and the PXRD peak list are provided in Table 2.

[0136] Table 2: List of the ten most intense PXRD peaks for Form A (Batch 103260-TC-01)

[0137]

[0138] *Data collected using copper K-alpha radiation. K-alpha II (K-alpha II) was arithmetically removed from the data before peak determination based on copper K-alpha I radiation. ).

[0139] Instruments and methods

[0140] FT-Raman spectroscopy was performed using a 1064 nm Nd:YVO 4 Excitation laser, InGaAs and liquid N 2 Raman spectra were collected on a Nicolet NXR9650 or NXR 960 spectrometer (Thermo Electron) with a cooled Ge detector and MicroStage. Neutral density filters and Happ-Genzel apodization functions and 2-stage zero filling were used at 4 cm -1 All spectra were acquired at 100-nm resolution and 64 to 256 scans.

[0141] Polarized light microscopy (PLM). Micrographs were collected using an Olympus BX60 polarized light microscope equipped with an Olympus DP70 camera.

[0142] Powder X-ray diffraction (PXRD) was performed using Ni-filtered Cu Ka (45 kV / 40 mA) radiation and a step size of 0.02° 2θ and an X'celerator TM The PXRD diffractograms were obtained on a PANalytical X'Pert Pro diffractometer with a RTMS (real-time multiple strip) detector. Configuration on the incident beam side: fixed divergence slit (0.25°), 0.04rad Soller slit, anti-scatter slit (0.25°), and 10 mm beam shield. Configuration on the diffracted beam side: fixed divergence slit (0.25°) and 0.04rad Soller slit. The sample was placed flat on a zero background Si wafer and covered with a Kapton film to comply with safety policies.

[0143] Powder X-Ray Diffraction (PXRD) Bruker. PXRD diffraction patterns were obtained on a Bruker D8 Advance system (SN: 2631) using Cu Ka (40 kV / 40 mA) radiation and a step size of 0.017° 2θ and a LynxEye detector. Configuration on the incident beam side: fixed divergence slit (0.2 mm), 4 mm Soller slit, beam knife. Configuration on the diffracted beam side: anti-scatter slit (8 mm) and 2.5° Soller slit. The sample was placed flat on a zero-background Si wafer.

[0144] Differential scanning calorimetry (DSC). At 40 ml / min N 2 DSC was performed using a TA Instruments Q100 differential scanning calorimeter equipped with an autosampler and refrigerated cooling system under purge. DSC thermograms were acquired at 15°C / min in an Al pleated pan unless otherwise indicated.

[0145] Thermogravimetric analysis (TGA). Unless otherwise indicated, the samples were analyzed in Pt or Al pans at 15 °C / min under 40 mL / min N 2 TGA thermograms were obtained using a TA Instruments Q500 thermogravimetric analyzer under purge.

[0146] Example 8: Unit Dosage of Injectable Allopregnanolone Pharmaceutical Composition

[0147] The first unit dose of the injectable allopregnanolone composition is packaged as a 100 mg / mL injectable solution in a 1 mL vial.

[0148] The second unit dose of the injectable allopregnanolone composition is packaged as a 200 mg / mL injectable solution in a 1 mL vial.

[0149] The third unit dose of the injectable allopregnanolone composition was packaged as a 300 mg / mL injectable solution in a 1 mL vial.

[0150] The fourth unit dose of the injectable allopregnanolone composition is packaged as a 350 mg / mL injectable solution in a 1 mL vial.

[0151] The fifth unit dose of the injectable allopregnanolone composition is packaged as a 400 mg / mL injectable solution in a 1 mL vial.

[0152] The sixth unit dose of the injectable allopregnanolone composition is packaged as a 500 mg / mL injectable solution in a 1 mL vial.

[0153] The seventh unit dose of the injectable allopregnanolone composition is packaged as a 550 mg / mL injectable solution in a 1 mL vial.

[0154] The eighth unit dose of the injectable allopregnanolone composition was packaged as a 600 mg / mL injectable solution in a 1 mL vial.

[0155] Numbered embodiments of the present disclosure

[0156] Other subject matter covered by the present disclosure is listed in the following numbered embodiments:

[0157] 1. A pharmaceutical composition comprising a pharmaceutically effective amount of a neuroactive steroid, wherein the neuroactive steroid is a γ-aminobutyric acid type A (GABA A ) receptor positive modulator; and wherein after intramuscular or subcutaneous injection of a single dose of the pharmaceutical composition, the neuroactive steroid reaches a maximum plasma concentration (C max ) and remain greater than the C max Plasma concentrations of about 5% of the drug persist for at least about 5 days.

[0158] 2. The pharmaceutical composition according to embodiment 1, wherein the single dose is about 0.5-50 mg per kg body weight.

[0159] 3. The pharmaceutical composition according to embodiment 2, wherein the single dose is in the range of about 1 to 8 mg per kg body weight.

[0160] 4. The pharmaceutical composition according to embodiment 2, wherein the single dose is in the range of about 2 to 6 mg per kg body weight.

[0161] 5. The pharmaceutical composition according to embodiment 2, wherein the single dose is in the range of about 3 to 5 mg per kg body weight.

[0162] 6. The pharmaceutical composition according to any one of embodiments 1-5, wherein the single dose is about 50 mg to 800 mg per unit dose.

[0163] 7. The pharmaceutical composition of embodiment 6, wherein the single dose is in the range of about 50 mg to about 450 mg per unit dose.

[0164] 8. The pharmaceutical composition of any one of embodiments 1-7, wherein the pharmaceutical composition has a neuroactive steroid concentration of at least about 100 mg / mL.

[0165] 9. The pharmaceutical composition of embodiment 8, wherein the neuroactive steroid concentration is in the range of about 100 mg / mL to about 800 mg / mL.

[0166] 10. A pharmaceutical composition according to any one of embodiments 1 to 7, wherein Said The neuroactive steroid reaches the C in about 30 minutes to 1 hour, 1 to 2 hours, 2 to 4 hours, or 4 to 6 hours. max .

[0167] 11. The pharmaceutical composition of embodiment 10, wherein the neuroactive steroid reaches the C in about 1 to 2 hours. max .

[0168] 12. A pharmaceutical composition according to any one of embodiments 1 to 11, wherein the neuroactive steroid maintains a concentration greater than the C max A plasma concentration of about 10%, 15%, 20%, 25% or 30% of that of the agent is maintained for at least about 10, 20, 30, 40, 50 or 60 days.

[0169] 13. A pharmaceutical composition according to embodiment 12, wherein the neuroactive steroid maintains a concentration greater than the C max Plasma concentrations of about 15% of the dose persist for at least about 30 days.

[0170] 14. A pharmaceutical composition according to any one of embodiments 1 to 13, wherein said C max Greater than 10ng / mL.

[0171] 15. The pharmaceutical composition of embodiment 5, wherein the single dose is in the range of 3 to about 5 mg / kg body weight, and wherein the neuroactive steroid maintains a plasma concentration of greater than about 10 ng / mL for at least about 5 days.

[0172] 16. A pharmaceutical composition according to embodiment 15, wherein the neuroactive steroid maintains a plasma concentration of greater than 10, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100 ng / mL for at least about 10, 20, 30, 40, 50 or 60 days.

[0173] 17. The pharmaceutical composition of any one of embodiments 15 to 16, wherein the neuroactive steroid maintains a plasma concentration of greater than 20 ng / mL for at least about 30 days.

[0174] 18. The pharmaceutical composition of any one of embodiments 1-15, wherein within about 1 hour of intramuscular or subcutaneous injection of a single dose of the pharmaceutical composition, the pharmaceutical composition releases less than about 5%-50% of the neuroactive steroid.

[0175] 19. The pharmaceutical composition of any one of embodiments 1-18, wherein the pharmaceutical composition has a relative bioavailability of about 2%-50% 24 hours after administration of the single dose by intramuscular or subcutaneous injection compared to the same dose administered intravenously.

[0176] 20. The pharmaceutical composition of any one of embodiments 1-19, wherein the pharmaceutical composition comprises a population of particles comprising the neuroactive steroid, wherein the particles have an average particle size of about 0.2-15 μm.

[0177] 21. The pharmaceutical composition of embodiment 20, wherein the particles have an average particle size of about 1.5-15 μm.

[0178] 22. The pharmaceutical composition of embodiment 21, wherein the particles have an average particle size of about 3-5 μm.

[0179] 23. The pharmaceutical composition of embodiment 20, wherein the particles have an average particle size of about 0.2-1.5 μm.

[0180] 24. The pharmaceutical composition of embodiment 23, wherein the particles have an average particle size of about 0.5-0.9 μm.

[0181] 25. The pharmaceutical composition of any one of embodiments 20-24, wherein at least 50%, 60%, 70%, 80% or 90% by weight of the particles have a particle size of about 0.2-15 μm.

[0182] 26. The pharmaceutical composition of any one of embodiments 20-25, wherein about 0.01 wt%-50 wt% of the particles have an average particle size of about 1.5-15 μm, and about 50 wt%-99.99 wt% of the particles have an average particle size of about 0.2-1.5 μm.

[0183] 27. A pharmaceutical composition as described in any one of embodiments 1-26, wherein the neuroactive steroid comprises tetrahydrodeoxycorticosterone (THDOC), androstane, androstane 3α-androstanediol, cholestane cholesterol, pregnane, ethinolone, allopregnanolone, ganaxolone, zuranosolone or any combination thereof.

[0184] 28. The pharmaceutical composition according to embodiment 27, wherein the neuroactive steroid is allopregnanolone.

[0185] 29. The pharmaceutical composition of any one of embodiments 1-28, wherein the pharmaceutical composition is substantially free of cyclodextrin.

[0186] 30. The pharmaceutical composition of embodiment 29, wherein the pharmaceutical composition is substantially free of sulfobutyl ether β-cyclodextrin.

[0187] 31. A pharmaceutical composition according to any one of embodiments 1-30, further comprising one or more pharmaceutically acceptable excipients.

[0188] 32. A pharmaceutical composition as in embodiment 31, wherein the one or more pharmaceutically acceptable excipients include binders, lubricants, glidants, disintegrants, diluents, colorants, surfactants, emulsifiers, fillers, carriers, isotonic agents, dispersants, viscosity regulators, resuspending agents, buffers or any combination thereof.

[0189] 33. A pharmaceutical composition according to embodiment 31 or 32, wherein the one or more pharmaceutically acceptable excipients include gum arabic, animal oil, benzyl alcohol, benzyl benzoate, calcium stearate, carbomer, cetearyl alcohol, cetyl alcohol, cholesterol, cyclodextrin, dextrose, diethanolamine, emulsifying wax, ethylene glycol palmitostearate, glycerol, glyceryl monostearate, glyceryl stearate, monoolein, monostearin, hydrate, histidine, hydrochloric acid, hydroxypropyl cellulose, hydroxypropyl-β-cyclodextrin (HPBCD), Hydroxypropyl methylcellulose (HPMC), lanolin, lanolin alcohol, lecithin, medium chain triglycerides, metal soap, methylcellulose, mineral oil, sodium dihydrogen phosphate, monoethanolamine, oleic acid, polyethylene glycol, polyoxyethylene-polyoxypropylene copolymer (poloxamer), polyoxyethylene alkyl ether, polyoxyethylene castor oil, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearate, polysorbate, polyoxyethylene (20) sorbitan monolaurate (Tween 20, polysorbate 20), polyoxyethylene (20) sorbitan monooleate (Tween 80, polysorbate 80), povidone, propylene glycol alginate, saline, sodium chloride, sodium citrate, sodium citrate dihydrate, sodium hydroxide, sodium lauryl sulfate, disodium hydrogen phosphate, sorbitan esters, stearic acid, stearyl alcohol, sunflower oil, tragacanth gum, triethanolamine, vegetable oil, water, xanthan gum or any combination thereof.

[0190] 34. A pharmaceutical composition according to any one of embodiments 1 to 33, comprising allopregnanolone polymorph A, characterized in that it has at least three of the peaks located at: 7.25, 8.88, 11.46, 14.50, 14.78, 17.77, 18.15, 18.32, 18.61 and 19.99 ± 0.1 ° 2θ in an X-ray powder diffraction (XRPD) diffraction pattern.

[0191] 35. The pharmaceutical composition according to any one of embodiments 1 to 33, wherein the pharmaceutical composition is a liquid suspension for intramuscular or subcutaneous injection.

[0192] 36. The pharmaceutical composition of embodiment 35, wherein the liquid suspension comprises the allopregnanolone polymorph A.

[0193] 37. A pharmaceutical composition according to any one of embodiments 34 to 36, wherein the allopregnanolone polymorph A has a chemical purity greater than 90%.

[0194] 38. A pharmaceutical composition according to any one of embodiments 34-37, wherein the allopregnanolone polymorph A has a melting point of about 170-180°C.

[0195] 39. The pharmaceutical composition of embodiment 38, wherein the allopregnanolone polymorph A has a melting point of about 174°C.

[0196] 40. A pharmaceutical composition as described in any one of embodiments 34-39, wherein the allopregnanolone polymorph A has peaks located at the following positions in the X-ray powder diffraction (XRPD) diffraction pattern: 7.25, 8.88, 11.46, 14.50, 14.78, 17.77, 18.15, 18.32, 18.61 and 19.99±0.1°2θ.

[0197] 41. A pharmaceutical composition as described in any one of embodiments 34-40, wherein the allopregnanolone polymorph A is crystallized from one or more solvents selected from the group consisting of: dichloromethane (DCM), tetrahydrofuran (THF), ethyl acetate (EtOAc), dimethyl sulfoxide (DMSO), toluene, 2-propanol:water (9:1), methanol (MeOH), 2-propanol (IPA), methyl tert-butyl ether (MTBE), isopropyl ether (IPE) and water.

[0198] 42. A method of treating a disease in a subject in need thereof, the method comprising: administering the pharmaceutical composition of any one of embodiments 1-41 to the subject by intramuscular or subcutaneous injection.

[0199] 43. A method of treating a disease in a subject in need thereof, the method comprising:

[0200] A pharmaceutical composition comprising a pharmaceutically effective amount of a neuroactive steroid is administered to the subject by intramuscular or subcutaneous injection in a single dose ranging from 0.5 to 10 mg per kg of body weight, wherein the neuroactive steroid is gamma-aminobutyric acid type A (GABA A ) receptor positive modulator; and wherein after said intramuscular or subcutaneous injection, said neuroactive steroid reaches a maximum plasma concentration (C max ) and remain greater than the C max Plasma concentrations of about 5% of the drug persist for at least about 5 days.

[0201] 44. The method of any one of embodiments 42-43, wherein the disease is selected from the group consisting of anxiety, mood disorders, major depression, postpartum disorders, Alzheimer's disease, Parkinson's disease, epilepsy, focal seizures, PCDH19 childhood epilepsy, childhood genetic epilepsy, CDKL5 deficiency (CDD), catamenial epilepsy, infantile spasms, fragile X syndrome, depression, postpartum depression, and premenstrual syndrome.

[0202] 45. The method of embodiment 44, wherein the disease is postpartum depression.

[0203] 46. ​​The method of embodiment 45, wherein the subject has a past history of depression.

[0204] 47. The method of embodiment 45 or 46, wherein the subject has a past history of postpartum depression.

[0205] 48. The method of any one of embodiments 42-47, wherein the administration is by a single intramuscular or subcutaneous injection.

[0206] 49. The method of any one of embodiments 42-47, wherein the pharmaceutical composition is administered to the subject within a time period ranging from 1 second to about 180 minutes.

[0207] 50. The method of embodiment 49, wherein the pharmaceutical composition is administered to the subject within a time period ranging from 1 second to about 30 minutes.

[0208] 51. The method of any one of embodiments 43-50, wherein the pharmaceutical composition is the pharmaceutical composition of any one of embodiments 1-41.

[0209] 52. Use of a composition comprising a neuroactive steroid for the manufacture of a medicament for treating a disease, wherein the composition is a pharmaceutical composition according to any one of embodiments 1 to 41.

[0210] 53. A composition comprising a neuroactive steroid for use in a method for treating a disease, wherein the neuroactive steroid is gamma-aminobutyric acid type A (GABA A ) receptor positive modulator; and wherein after intramuscular or subcutaneous injection of a single dose of the neuroactive steroid, the neuroactive steroid reaches a maximum plasma concentration (C max ) and remain greater than the C max Plasma concentrations of about 5% of the drug persist for at least about 5 days.

[0211] 54. The composition of embodiment 53, wherein the composition is a pharmaceutical composition of any one of embodiments 1-41.

[0212] 55. The composition of embodiment 53, wherein the method is the method of any one of embodiments 42-51.

[0213] 56. A method for producing a pharmaceutical composition according to any one of embodiments 1-41, the method comprising:

[0214] a) mixing a composition comprising the neuroactive steroid with one or more pharmaceutically acceptable excipients; and

[0215] b) milling the composition to produce a population of particles of the pharmaceutical composition.

[0216] 57. A method for producing a pharmaceutical composition according to any one of embodiments 1-41, the method comprising:

[0217] a) milling a composition comprising the neuroactive steroid to produce a population of particles; and

[0218] b) mixing the composition with one or more pharmaceutically acceptable excipients to produce the pharmaceutical composition.

[0219] 58. A method for producing the pharmaceutical composition of any one of embodiments 34-40, the method comprising: crystallizing the allopregnanolone polymorph A from one or more solvents selected from the group consisting of dichloromethane (DCM), tetrahydrofuran (THF), ethyl acetate (EtOAc), dimethyl sulfoxide (DMSO), toluene, 2-propanol:water (9:1), methanol (MeOH), 2-propanol (IPA), methyl tert-butyl ether (MTBE), isopropyl ether (IPE) and water.

[0220] 59. The method according to embodiment 58, further comprising:

[0221] a) mixing the allopregnanolone polymorph A with one or more pharmaceutically acceptable excipients to form a composition; and

[0222] b) milling the composition to produce a population of particles of the pharmaceutical composition.

[0223] 60. The method according to embodiment 58, further comprising:

[0224] a) grinding a composition comprising said allopregnanolone polymorph A to produce a population of particles; and

[0225] b) mixing the composition with one or more pharmaceutically acceptable excipients to produce the pharmaceutical composition.

[0226] 61. The method of any one of embodiments 56-60, wherein the pharmaceutical composition is a liquid suspension for intramuscular or subcutaneous injection.

[0227] The various embodiments described above can be combined to provide other embodiments. All U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications, and non-patent applications mentioned in this specification and / or listed in the application data sheet are incorporated herein by reference in their entirety. Aspects of the embodiments can be modified, if necessary, to adopt the concepts of the various patents, applications, and publications to provide other embodiments.

Claims

1. A pharmaceutical composition comprising 100 mg / mL to 800 mg / mL of allopregnanolone polymorph A, a particle population containing the allopregnanolone polymorph A, and a pharmaceutically acceptable excipient, wherein: The particle population comprises the allopregnanolone polymorph A having an average particle size (D50) in the range of 1.2-6 μm, and the allopregnanolone polymorph A has a peak located at the following in an X-ray powder diffraction (XRPD) diffraction pattern: 7.25, 8.88, 11.46, 14.50, 14.78, 17.77, 18.15, 18.32, 18.61 and 19.99 ± 0.1° 2θ, the pharmaceutically acceptable excipients comprising poloxamer, polyethylene glycol, isotonic agent and buffer; After a single dose of the pharmaceutical composition is injected intramuscularly or subcutaneously, the allopregnanolone polymorph A reaches a maximum plasma concentration (C max ) and remain greater than the C max Plasma concentrations of 5% persist for at least 5 days.

2. The pharmaceutical composition of claim 1, wherein the single dose comprises allopregnanolone polymorph A in the range of 0.5-50 mg per kg body weight.

3. The pharmaceutical composition of claim 2, wherein the single dose comprises allopregnanolone polymorph A in the range of 1 to 8 mg per kg body weight.

4. The pharmaceutical composition of claim 2, wherein the single dose comprises allopregnanolone polymorph A in the range of 2 to 6 mg per kg body weight.

5. The pharmaceutical composition of claim 2, wherein the single dose comprises allopregnanolone polymorph A in the range of 3 to 5 mg per kg body weight.

6. The pharmaceutical composition of claim 1, wherein the single dose comprises 50 mg to 800 mg of allopregnanolone polymorph A per unit dose.

7. The pharmaceutical composition of claim 6, wherein the single dose comprises allopregnanolone polymorph A in the range of 50 mg to 450 mg per unit dose.

8. The pharmaceutical composition of any one of claims 1-7, wherein the pharmaceutical composition has a concentration of allopregnanolone polymorph A of 100 mg / mL to 400 mg / mL.

9. The pharmaceutical composition of claim 8, wherein the concentration of allopregnanolone polymorph A is 300 mg / mL.

10. The pharmaceutical composition of any one of claims 1 to 7, wherein after a single dose of the pharmaceutical composition is injected intramuscularly or subcutaneously, the allopregnanolone polymorph A reaches a C of 1.5 to 2.5 within 30 minutes to 1 hour, 1 to 2 hours, 2 to 4 hours or 4 to 6 hours. max .

11. The pharmaceutical composition of claim 10, wherein the allopregnanolone polymorph A reaches the C in 1 to 2 hours. max .

12. The pharmaceutical composition of any one of claims 1 to 7, wherein the allopregnanolone polymorph A remains greater than the C max The invention also provides for a plasma concentration of 10%, 15%, 20%, 25% or 30% of that of the agent for at least 10, 20, 30, 40, 50 or 60 days.

13. The pharmaceutical composition of claim 12, wherein the allopregnanolone polymorph A remains greater than the C max Plasma concentrations of 15% persist for at least 30 days.

14. The pharmaceutical composition according to any one of claims 1 to 7, wherein the C max Greater than 10ng / mL.

15. The pharmaceutical composition of claim 5, wherein the single dose is in the range of 3 to 5 mg per kg body weight, and wherein the allopregnanolone polymorph A maintains a plasma concentration of greater than 10 ng / mL for at least 5 days.

16. The pharmaceutical composition of claim 15, wherein the allopregnanolone polymorph A maintains a plasma concentration of greater than 10, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100 ng / mL for at least 10, 20, 30, 40, 50 or 60 days.

17. The pharmaceutical composition of claim 15 or 16, wherein the allopregnanolone polymorph A maintains a plasma concentration of greater than 20 ng / mL for at least 30 days.

18. The pharmaceutical composition of any one of claims 1 to 7, wherein the pharmaceutical composition releases less than 5% to 50% of the allopregnanolone polymorph A within 1 hour after a single dose of the pharmaceutical composition is injected intramuscularly or subcutaneously.

19. The pharmaceutical composition of any one of claims 1-7, wherein the pharmaceutical composition has a relative bioavailability of 2%-50% 24 hours after a single dose by intramuscular or subcutaneous injection compared to the same dose administered intravenously.

20. The pharmaceutical composition of any one of claims 1-7, wherein the particles have an average particle size of 3-5 μm.

21. The pharmaceutical composition of any one of claims 1-7, wherein the pharmaceutical composition is substantially free of cyclodextrin.

22. The pharmaceutical composition of claim 21, wherein the pharmaceutical composition is substantially free of sulfobutyl ether β-cyclodextrin.

23. The pharmaceutical composition of any one of claims 1-7, further comprising one or more pharmaceutically acceptable excipients.

24. The pharmaceutical composition of any one of claims 1-7, wherein the pharmaceutical composition is a liquid suspension for intramuscular or subcutaneous injection.

25. The pharmaceutical composition of any one of claims 1-7, wherein the allopregnanolone polymorph A has a chemical purity greater than 90%.

26. The pharmaceutical composition of any one of claims 1-7, wherein the allopregnanolone polymorph A has a melting point of 170-180°C.

27. The pharmaceutical composition of claim 26, wherein the allopregnanolone polymorph A has a melting point of 174°C.

28. The pharmaceutical composition of any one of claims 1-7, wherein the allopregnanolone polymorph A has peaks in an X-ray powder diffraction (XRPD) diffraction pattern at 7.25, 8.88, 11.46, 14.50, 14.78, 17.77, 18.15, 18.32, 18.61 and 19.99 ± 0.1 ° 2θ.

29. The pharmaceutical composition of any one of claims 1-7, wherein the allopregnanolone polymorph A is crystallized from one or more solvents selected from the group consisting of dichloromethane (DCM), tetrahydrofuran (THF), ethyl acetate (EtOAc), dimethyl sulfoxide (DMSO), toluene, 2-propanol:water (9:1), methanol (MeOH), 2-propanol (IPA), methyl tert-butyl ether (MTBE), isopropyl ether (IPE) and water.

30. Use of the pharmaceutical composition according to any one of claims 1 to 29 in the preparation of a medicament for treating a disease in a subject, wherein: The disease is a central nervous system disorder.

31. Use of a pharmaceutical composition comprising a pharmaceutically effective amount of allopregnanolone polymorph A in the preparation of a medicament for treating a disease in a subject, wherein: The pharmaceutical composition comprises 100 mg / mL to 800 mg / mL of allopregnanolone polymorph A, a particle population containing the allopregnanolone polymorph A, and a pharmaceutically acceptable excipient, wherein the particle population comprises the allopregnanolone polymorph A with an average particle size (D50) in the range of 1.2-6 μm, and the allopregnanolone polymorph A has peaks located at the following positions in an X-ray powder diffraction (XRPD) diffraction pattern: 7.25, 8.88, 11.46, 14.50, 14.78, 17.77, 18.15, 18.32, 18.61 and 19.99±0.1°2θ; the pharmaceutically acceptable excipient comprises poloxamer, polyethylene glycol, an isotonic agent and a buffer; the disease is a central nervous system disorder; After a single dose of the pharmaceutical composition is injected intramuscularly or subcutaneously, the allopregnanolone polymorph A reaches a maximum plasma concentration (C max ) and remain greater than the C max 5% of plasma concentration for at least 5 days; and The pharmaceutical composition is administered to the subject by intramuscular or subcutaneous injection in a single dose ranging from 0.5 to 10 mg per kg body weight.

32. The use of claim 30 or 31, wherein the disease is selected from the group consisting of anxiety, mood disorders, Alzheimer's disease, Parkinson's disease, epilepsy, CDKL5 deficiency (CDD), fragile X syndrome, depression and premenstrual syndrome.

33. The use of claim 32, wherein the depression is major depression or postpartum depression.

34. The method of claim 32, wherein the epilepsy comprises focal epileptic seizures, PCDH19 childhood epilepsy, catamenial epilepsy, infantile spasms or childhood genetic epilepsy.

35. The use according to claim 30 or 31, wherein the disease is postpartum depression.

36. The use of claim 35, wherein the subject has a history of depression.

37. The use of claim 35, wherein the subject has a history of postpartum depression.

38. The use of claim 30 or 31, wherein the pharmaceutical composition is administered to the subject by a single intramuscular or subcutaneous injection.

39. The use of claim 30 or 31, wherein the pharmaceutical composition is administered to the subject within a time period ranging from 1 second to 180 minutes.

40. The use of claim 39, wherein the pharmaceutical composition is administered to the subject within a time period ranging from 1 second to 30 minutes.

41. The use of claim 30, wherein the pharmaceutical composition is administered to the subject in a single dose ranging from 0.5 to 10 mg per kg body weight.

42. The use of claim 31, wherein the pharmaceutical composition is substantially free of cyclodextrin.

43. The use of claim 42, wherein the pharmaceutical composition is substantially free of sulfobutyl ether β-cyclodextrin.

44. A method for producing the pharmaceutical composition of any one of claims 1-29, the method comprising: a) mixing the allopregnanolone polymorph A with one or more pharmaceutically acceptable excipients to obtain a mixture; and b) milling the mixture to produce a population of particles of the pharmaceutical composition.

45. A method for producing the pharmaceutical composition of any one of claims 1-29, the method comprising: a) grinding the allopregnanolone polymorph A to produce a population of particles; and b) mixing the population of particles with one or more pharmaceutically acceptable excipients to produce the pharmaceutical composition.

46. ​​A method for producing the pharmaceutical composition of any one of claims 1-29, the method comprising: Allopregnanolone polymorph A is crystallized from one or more solvents selected from the group consisting of dichloromethane (DCM), tetrahydrofuran (THF), ethyl acetate (EtOAc), dimethyl sulfoxide (DMSO), toluene, 2-propanol:water (9:1), methanol (MeOH), 2-propanol (IPA), methyl tert-butyl ether (MTBE), isopropyl ether (IPE) and water.

47. The method of claim 46, further comprising: a) mixing the allopregnanolone polymorph A with one or more pharmaceutically acceptable excipients to form a composition; and b) milling the composition to produce a population of particles of the pharmaceutical composition.

48. The method of claim 46, further comprising: a) grinding a composition comprising said allopregnanolone polymorph A to produce a population of particles; and b) mixing the composition with one or more pharmaceutically acceptable excipients to produce the pharmaceutical composition.

49. The method of any one of claims 44-48, wherein the pharmaceutical composition is a liquid suspension for intramuscular or subcutaneous injection.